---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description. Covers Product description and Place of product in therapy. 242 evidence topics quoted from 102 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; registrational phase 3 EMERGE trial ongoing, with top-line results expected in the second half of 2028

> “In June 2026, we announced the initiation of the Phase 3 registrational EMERGE trial of claseprubart in gMG. We expect to report top-line results from this trial in the second half of 2028.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in 2H’28”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

> “EMERGE is a global Ph. 3 trial evaluating Q4W and Q2W S.C. claseprubart in AChR+ gMG; top-line data 2H’28”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Investigational status

> “Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-2.1.1-4"></a>

##### Planned update to EMERGE top-line guidance by the end of 2027

> “Claseprubart Updated Ph. 3 EMERGE top-line guidance (YE’27)”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.1-5"></a>

##### Orphan drug designation for myasthenia gravis, May 2026

> “On May 1, 2026, claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Orphan Drug Designation granted: Claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis.”

Source: [Dianthus Therapeutics (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm)

<a id="topic-2.1.1-6"></a>

##### Fast track or breakthrough therapy designation for generalized myasthenia gravis

No evidence found.

<a id="topic-2.1.1-7"></a>

##### Phase 2 MaGic trial initiated after FDA IND clearance, February 2024

> “today announced the initiation of the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis. The initiation follows U.S. Food and Drug Administration (FDA) clearance of the Phase 2 Investigational New Drug (IND) application for DNTH103.”

Source: [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)

<a id="topic-2.1.1-8"></a>

##### Phase 2 MaGic top-line results, September 2025

> “Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13”
> “we are planning for an end-of-Phase 2 meeting with the FDA to align on the proposed design of a Phase 3 trial for claseprubart in Myasthenia Gravis that investigates both 300mg Q2W and 300mg Q4W doses vs.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-2.1.1-9"></a>

##### End-of-phase 2 meeting with the FDA, first quarter of 2026

> “In September 2025, we reported positive top-line results from the Phase 2 MaGic trial of claseprubart for patients with gMG and subsequently held an end-of-Phase 2 meeting with the FDA in the first quarter of 2026.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “No ANA screening exclusion criteria or routine ANA testing during RCT or OLE, inclusion criteria of MG-ADL of ≥6 and QMG of ≥10, and 17-week S.C. treatment period per alignment with FDA”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.1-10"></a>

##### Phase 3 EMERGE trial initiated, June 2026

> “today announced initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (gMG).”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

> “Study Start (Actual) 2026-06-29”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.1-11"></a>

##### FDA written feedback on antinuclear antibody screening and drug-induced lupus, March 2026

> “Removal of anti-nuclear antibodies ("ANAs") as a screening criteria, a common reason for screen failure across all three claseprubart programs”
> “Removal of routine ANA testing during claseprubart clinical trials”
> “Reclassification of the hypothetical risk of systemic lupus erythematosus ("SLE") to drug-induced lupus ("DIL")”
> “In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials.”

Source: [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)

<a id="topic-2.1.1-12"></a>

##### Other indications in development

> “Dianthus is building a neuromuscular franchise with claseprubart and expects to report top-line results from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in December ’26, report top-line results from the Phase 3 CAPTIVATE trial Part A in CIDP by YE’27 and from Part B by YE’28, and report top-line results from the Phase 3 EMERGE trial in generalized Myasthenia Gravis in 2H’28.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Dianthus Therapeutics

> “Our most advanced product candidate, claseprubart, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “About Claseprubart (DNTH103) Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name: proposed and recommended international nonproprietary name

> “claseprubart”
> “immunoglobulin G4-kappa, anti-[Homo sapiens C1S (complement C1s)], Homo sapiens monoclonal antibody”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

> “RECOMMENDED International Nonproprietary Names: List 94”
> “immunoglobulin G4-kappa, anti-[Homo sapiens C1S (complement C1s)], Homo sapiens monoclonal antibody”

Source: [WHO Drug Information Recommended INN List 94 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl94.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Development code

> “Drug: Claseprubart IV Infusion Other Names: DNTH103”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.1-4"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-5"></a>

###### Structure: fully human IgG4-kappa antibody with an engineered Fc domain

> “Claseprubart is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “hinge 1-12 S10>P (225)”
> “M15.1>Y (249), S16>T (251), T18>E (253)”
> “produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

<a id="topic-2.1.2.1-6"></a>

###### Therapeutic class: classical complement pathway inhibitor targeting active C1s

> “Highly potent, ~8-week half-life, Classical Pathway (CP) inhibitor targeting active C1s”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Intravenous loading dose followed by subcutaneous injection

> “Dosing: 15 or 20mg/kg I.V. Loading Dose followed by 300mg/2mL or 600mg/4mL S.C. Q2W starting Day 7”
> “Target dose of 300mg/2mL Q2W will be in Ph. 3 study”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Claseprubart intravenous (IV) loading dose on Day 1. Claseprubart subcutaneous (SC) once every 2 weeks for up to 13 weeks.”
> “Drug: Claseprubart IV Infusion”
> “Drug: Claseprubart SC injection”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.2-2"></a>

###### Phase 3 subcutaneous presentation: prefilled syringe

> “Combination Product: Claseprubart Prefilled syringe containing claseprubart for SC administration”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.2-3"></a>

###### Target commercial presentation: 300 mg/2 mL autoinjector

> “Targeting convenience of a single, self-administered S.C. 300mg/2mL autoinjector dosed every 2 or 4 weeks”
> “Targeting single 300mg/2mL self-administered S.C. Q2W”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO INN class statement for claseprubart

> “claseprubart”
> “immunosuppressant”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

<a id="topic-2.1.2.4-2"></a>

###### WHO INN stem and target-class infix for monoclonal antibodies

> “The suffix is preceded by an infix that indicates the target class.”
> “The suffix -bart is used for monospecific full-length immunoglobulins with engineered amino acid changes in the constant regions and identical sets of CDRs that recognize the same epitope.”
> “altered neonatal Fc receptor (FcRn) binding”
> “-pru- immunosuppressive”

Source: [WHO INN monoclonal antibody nomenclature scheme (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_nomenclature-_2021rev.pdf)

<a id="topic-2.1.2.4-3"></a>

###### WHO Anatomical Therapeutic Chemical group for complement inhibitors

| ATC code | Name |
| --- | --- |
| “L04AJ” | “Complement inhibitors” |
| “L04AJ01” | “eculizumab” |
| “L04AJ02” | “ravulizumab” |
| “L04AJ04” | “sutimlimab” |
| “L04AJ06” | “zilucoplan” |

Source: [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L04AJ)

<a id="topic-2.1.2.4-4"></a>

###### AHFS class and ATC code assigned to claseprubart

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication under study: adults with acetylcholine receptor antibody-positive generalized myasthenia gravis

> “The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

> “EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial in approximately 195 participants with generalized Myasthenia Gravis who are acetylcholine receptor antibody positive (AChR+).”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

<a id="topic-2.1.2.5-2"></a>

###### Eligible population: phase 3 EMERGE inclusion criteria

> “Diagnosis of gMG by the following tests: Acetylcholine receptor antibody (AChR Ab) positive, and One of the following: i. History of abnormal neuromuscular transmission test; ii. History of positive anticholinesterase test; iii. Clinical response to acetylcholinesterase inhibitors.”
> “Myasthenia Gravis Foundation of America (MGFA) Class II-IVa MG-ADL scale score of 6 or more QMG scale score of 10 or more”
> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and based on vaccine availability”
> “Ages Eligible for Study 18 Years to 80 Years”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.5-3"></a>

###### Size of the AChR antibody-positive population as the company states it

> “Over 100,000 people in the U.S. are living with gMG and approximately 85% have AChR autoantibody-driven disease.”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Selective binding to the active form of C1s

> “Our most advanced product candidate, claseprubart, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. The active form of C1s is generated during complement activation by cleavage of the inactive proC1s. As a validated complement target in the autoimmune and inflammatory field, C1s inhibition prevents further progression of the classical pathway cascade.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Role of C1s in the classical complement pathway

> “Classical pathway activation is initiated by the C1 complex. The C1 complex consists of a binding protein, C1q, and two inactive proenzymes, C1r”
> “Initiation of the classical pathway cascade occurs when C1q binds to the Fc portion of immunoglobulin G”
> “In its active form, C1s is responsible for cleaving and activating C4 and C2, which leads to the downstream cascade that culminates in the terminal pathway and MAC formation. C1s is unique to the classical pathway and thus provides a therapeutic opportunity to selectively target antibody-driven autoimmune and inflammatory disorders mediated by the classical pathway while leaving the lectin and alternative pathways intact.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.6.1-3"></a>

###### Targeting of the small active fraction of circulating C1s

> “By selectively targeting only the active form of C1s, which drives disease pathology and constitutes only a small fraction of the total protein present in circulation, we aim to reduce the amount of drug required for a therapeutic effect.”
> “DNTH103 is designed to selectively target the active form of C1s, inhibiting only the classical pathway, while leaving the lectin and alternative pathways intact.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-2.1.2.6.1-4"></a>

###### Binding selectivity for active C1s over proC1s

> “High selectivity and potency >10,000-fold binding affinity for Active C1s versus proC1s Picomolar binding affinity”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.1-5"></a>

###### Upstream blockade of C3a, C3b, and membrane attack complex formation

> “Selectively targets start of the classical complement pathway, thereby blocking MAC formation and C3a/C3b pro-inflammatory complement components”
> “No impact on lectin or alternative pathways, potentially preserving complement- mediated defense against encapsulated bacteria infection”
> “C2 inhibitors block both the classical and lectin pathways”
> “C5 inhibitors impact all three complement pathways, including classical, lectin and alternative”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.1-6"></a>

###### Company description of the mechanism: latest statement

> “Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target.”
> “Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Classical pathway inhibition in healthy volunteers: phase 1

> “DNTH103 showed dose-dependent inhibition of the classical pathway measured by CH50 inhibition and Wieslab® assay”
> “Phase 1 data confirm • ~60-day half-life • IC90 calculated at 87μg/mL • Dosing modeled • 15mg/kg IV on Day 0 • 300mg SC Q2W starting Day 7”

Source: [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)

<a id="topic-2.1.2.6.2-2"></a>

###### In vitro affinity and potency compared with riliprubart

| Assay | Claseprubart (DNTH103) | Riliprubart |
| --- | --- | --- |
| Binding affinity to human active C1s, KD (KinExa) | “9pM” | “75pM” |
| Binding affinity to human active C1s, KD (SPR) | “8pM” | “35pM” |
| C4 cleavage by human active C1s, IC90 (nM) | “0.47” | “3.69” |
| Wieslab classical pathway assay in human serum, IC90 (μg/mL) | “0.45” | “5.4” |
| CH50 assay of RBC lysis in human serum, IC90 (μg/mL) | “98” | “668” |
| Liposome lysis in human serum, IC90 (μg/mL) | “14.7” | “39.8” |

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.2-3"></a>

###### Neurotransmission and muscle contraction in an in vitro myasthenia gravis model

> “Serum from MG patients used in a validated commercially available humanized in-vitro MG model1,2,3 simulating a relevant clinical phenotype of impaired neurotransmission and muscle contraction • 7 MG patient sera samples were collected; 3 were AChR+ and used in the study • Evaluated response to anti-C5 antibody§ and DNTH103 via fatigue index (measures neurotransmission and muscle contraction)”
> “A reduction in fatigue index indicates improvement in neurotransmission and muscle contraction”
> “DNTH103 is a highly potent picomolar inhibitor of active C1s that is as effective in neurotransmission and muscle contraction as an anti-C5 antibody in a preclinical model of Myasthenia Gravis”

Source: [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)

| Treatment with AChR+ MG patient sera | Change in muscle contraction fatigue index from baseline |
| --- | --- |
| Ravulizumab* (1 μM), n=3 | “-14.8%” |
| DNTH103 (0.1 μM), n=3 | “-24.8%” |
| DNTH103 (1 μM), n=3 | “-27.8%” |

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.2-4"></a>

###### Upstream versus downstream complement blockade: C3a, C3b, and membrane attack complex

> “To determine whether aC1s inhibition by claseprubart suppresses generation of C3a, C3b and membrane attack complex (MAC) in vitro, and whether its complement inhibition profi le is different to that of the C5 inhibitor ravulizumab.”
> “In head-to-head WIESLAB® Complement Classical Pathway assays, claseprubart produced comparable inhibition of MAC formation compared to ravulizumab, confirming similar levels of terminal pathway blockade (Figure 2).”
> “In contrast, only upstream aC1s inhibition with claseprubart resulted in near complete inhibition of the generation of C3a, while ravulizumab did not (Figure 3).”
> “Similarly, in the C3b assay, C3b-positive RBCs were all but undetectable in claseprubart-treated assay samples, but levels were unaffected in samples treated with ravulizumab (Figure 4).”

Source: [Shelly et al. (2026)](https://investor.dianthustx.com/static-files/1c8f7991-8993-4f05-8d16-194596a7c8c4)

<a id="topic-2.1.2.6.2-5"></a>

###### Exposure and response in the MaGic open-label extension

> “PK of ~65 μg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 μg/mL • Robust reductions in MG-ADL and QMG are achieved by week 4, after just two 600mg/4mL doses and remain stable in subsequent weeks • Growing external evidence further supports that lower levels of complement inhibition (<90%) may be sufficient for efficacy in gMG”
> “PK levels approximately half of 300mg/2mL Q2W steady state resulted in robust reductions on MG-ADL & QMG”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “A robust MG-ADL decline at week 4 in the open-label extension (OLE) of -2.5 points and QMG score reduction of -3.2 points for patients on placebo during the RCT who received only two doses of claseprubart 600mg/4mL Q2W without a loading dose and achieved a PK level far below the steady state of 300mg/2mL Q2W, supporting potential for Q4W dosing of 300mg/2mL”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Fc engineering for half-life extension

> “Claseprubart is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic”
> “profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “YTE, 3 amino acid substitutions at positions 249, 251 and 253 in the IgG4 heavy chain constant region (M249Y/S251T/T253E)”

Source: [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)

<a id="topic-2.1.2.6.3-2"></a>

###### Phase 1 study design for pharmacokinetic assessment

> “We evaluated DNTH103 in a first-in-human Phase 1 single ascending dose”
> “clinical trial in New Zealand to explore the safety, tolerability, PK, and pharmacodynamics”
> “We reported data from 60 healthy volunteers that have been dosed across eight cohorts, including six SAD cohorts: 1mg/kg intravenous”
> “10mg/kg I.V., 30mg/kg I.V., 50mg/kg I.V., 300mg S.C. and 600mg S.C.; and two MAD cohorts: 300mg S.C. and 600mg. S.C.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-2.1.2.6.3-3"></a>

###### Elimination half-life of approximately 60 days

> “Additionally, based on data from this clinical trial, DNTH103 has a half-life of approximately 60 days.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “The top-line data confirmed its approximately 60-day half-life and highly potent classical pathway inhibition with Q2W S.C. dosing of 300mg/2mL surpassing the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay estimated to be 87ug/mL”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “Highly potent, ~8-week half-life, Classical Pathway (CP) inhibitor targeting active C1s”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.3-4"></a>

###### Dose proportionality and accumulation in phase 1

> “I.V. SAD: Linear PK with Exposure Proportional Across Doses S.C. MAD: Strong Accumulation with Q2W Dosing PK/PD: Analysis Demonstrates IC90 of 87 µg/mL Data comprised of 60 HVs from 8 cohorts”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.3-5"></a>

###### Simulated steady-state exposure relative to the IC90

> “With these data, we conducted a PK simulation that demonstrates the steady state serum concentration of DNTH103, when dosed 300mg S.C. Q2W following an initial I.V. loading dose, exceeds the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay”
> “estimated to be 87ug/mL. We believe, based on published scientific literature related to other complement therapies, that the IC90 will be sufficient to achieve clinical activity in patients with gMG, CIDP, and MMN.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “Simulation using data from 60 healthy volunteers dosed across multiple cohorts demonstrates potent inhibition with infrequent S.C. dosing IC90 – 87 µg/mL Day 0: 15mg/kg I.V. Starting Day 7: 300mg S.C. Q2W Dosing Modeled”
> “300mg and 600mg S.C. Q2W dosing surpasses IC90 (87 µg/mL) and IC95 (149 µg/mL), respectively”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.3-6"></a>

###### Observed steady-state concentration with 300 mg every 2 weeks: phase 2

> “PK of ~65 μg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 μg/mL”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA written feedback on antinuclear antibody testing and the autoimmune risk description

> “In addition, in the first quarter of 2026, the Company proposed to the Food & Drug Administration”
> “the following changes to screening criteria and required routine labs, and the description of the hypothetical autoimmune safety risk across claseprubart clinical trials, based on patient experience to date and scientific consensus from published data:”
> “a common reason for screen failure across all three claseprubart programs; 2. Removal of routine ANA testing during claseprubart clinical trials; and 3. Reclassification of the hypothetical risk of systemic lupus erythematosus”
> “a side effect in several classes of widely used medications characterized by the reversal of symptoms upon discontinuation of the precipitating medication. In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials. Of note there have been no cases of either SLE or DIL to date in any claseprubart program.”

Source: [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)

<a id="topic-2.1.2.7.1-2"></a>

###### Antinuclear antibody seroconversion: phase 2 randomized period

| Measure | Placebo (N=22) | Claseprubart 300mg/2mL Q2W (N=21) | Claseprubart 600mg/4mL Q2W (N=22) |
| --- | --- | --- | --- |
| Newly positive for anti-nuclear antibodies (ANA) | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Represents participants who were ANA negative at baseline and tested positive at ≥1:320 at any point during RCT (percentages calculated from n=17 for 300mg arm and n=22 for 600mg arm). An ANA titer of ≥1:320 was an exclusion criterion for the clinical trial protocol. At end of RCT (Week 13), 2 of the 8 patients in 600mg arm tested negative for ANA, 2 of the 8 patients in 600mg arm remained positive but at <1:320.”
> “Drug-Induced Lupus (DIL) is an autoimmune syndrome triggered by specific medications, such as statins, TNF-alpha inhibitors, and ACE inhibitors/beta-blockers. A key distinguishing feature of DIL is its reversibility, as symptoms typically resolve once the offending medication is withdrawn.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.7.1-3"></a>

###### Antinuclear antibody testing removed from current trial protocols

> “No ANA screening exclusion criteria or routine ANA testing during the RCT or OLE”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.7.1-4"></a>

###### Infection risk: rationale for sparing the lectin and alternative pathways

> “As a result, DNTH103 may have a reduced risk of infections from encapsulated bacteria when compared to C5 terminal inhibitors, thus potentially avoiding an FDA Boxed Warning and associated Risk Evaluation and Mitigation Strategy”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-2.1.2.7.1-5"></a>

###### Infection risk: in vitro meningococcal killing assay

> “DNTH103 in vitro study demonstrates lower risk of Neisseria meningitidis infections”
> “N. meningitidis bacterial killing is unaffected despite inhibition of the classical pathway”
> “In this assay, DNTH103 maintained bacterial killing, potentially leading to a decreased risk of infection vs. anti-C5 antibody*”

Source: [Vissing et al. (2024)](https://investor.dianthustx.com/static-files/0ec7e0cd-6d44-419f-b020-01f204c56da3)

<a id="topic-2.1.2.7.1-6"></a>

###### Infection and autoimmune events reported in clinical trials to date

> “In addition, claseprubart was generally well tolerated with no related serious infections, no clinical symptoms of DIL, no related SAEs or discontinuations due to safety.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Safety and tolerability of claseprubart in the OLE was consistent with the RCT, including no meningococcal infections.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-2.1.2.7.1-7"></a>

###### Trial precautions: vaccination, complement deficiency, meningococcal history, and lupus

> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and based on vaccine availability”
> “Known complement deficiency Prior history (at any time) of N. meningitidis infection”
> “Diagnosis of systemic lupus erythematosus (SLE) or family history (defined as a parent, sibling, or child) of SLE”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.7.1-8"></a>

###### Extended half-life and duration of adverse effects

> “In addition, a half-life extension could prolong the duration of undesirable side effects, which could also inhibit market acceptance.”
> “An extended half-life may make it more difficult for patients to change treatments and there is a perception that half-life extension could exacerbate side effects, each of which may adversely affect our ability to gain market acceptance.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age ranges studied in claseprubart trials

> “Ages Eligible for Study 18 Years to 80 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

> “Adult males and females, 18 to 75 years of age (inclusive) at Screening.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-2.1.2.8-2"></a>

###### Body weight ranges studied

> “Weight range between 40-130 kg at Screening”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.8-3"></a>

###### Pregnancy and contraception requirements in trials

> “Female participants must be of non-childbearing potential, or if of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of contraception”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.8-4"></a>

###### Pregnancy, lactation, renal function, and hepatic function: phase 1 exclusions

> “Estimated creatinine clearance (CrCl) < 60 mL/min during Screening or at check-in day (Day -1) using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.”
> “Liver test results during Screening or at check-in day (Day 1) that are elevated more than 1.5-fold above the ULN for gamma glutamyl transferase, bilirubin (total), aspartate aminotransferase (AST) or alanine aminotransferase (ALT), unless a diagnosis of Gilbert syndrome.”
> “For women of childbearing potential (WOCBP), a positive serum pregnancy test at the Screening visit or a positive urine pregnancy test (with confirmatory serum pregnancy test) at check-in (Day -1).”
> “Females who are breastfeeding or planning to breast feed at any time during the study.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Claseprubart

<a id="topic-2.1.2.9.1-1"></a>

###### Intravenous immunoglobulin: phase 1 Part C pharmacokinetic study

> “Part A and Part B have already been registered and this registration of Part C will be evaluating DNTH103 PK following administration of human normal immunoglobulin (Ig)G. Part C will be open label and will not be placebo controlled.”
> “Single dose DNTH103, administered on Day 1 after administration of Privigen NZ solution for IV infusion on Days -8 and -7”
> “IV7, 0.5 g/kg of body weight per day for 2 consecutive days (total dose: 1 g/kg)”
> “Investigational Product: DNTH103 IV infusion, 1 week after Privigen NZ solution: • IV7, 10 mg/kg Investigational Product: DNTH103 SC injection, 1 week after Privigen NZ solution: • IV7, 600 mg”
> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV following administration of IgG, as a single dose in healthy adult volunteers.”
> “Recruitment status Completed”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-2.1.2.9.1-2"></a>

###### Prior FcRn blockers, complement inhibitors, rituximab, immunoglobulin, and plasma exchange: phase 2 exclusions

> “Individuals with current or prior use of a complement inhibitor, use of an anti-neonatal Fc receptor agent within 90 days of randomization, use of rituximab within 6 months, or IV immunoglobulin/plasma exchange within 4 weeks of randomization were not permitted to participate in the study.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-2.1.2.9.1-3"></a>

###### Prior B-cell therapies, immunoglobulin, and plasma exchange: EMERGE exclusions

> “Rituximab or other B-cell targeting therapies (ie, inebilizumab) within 6 months (180 days) prior to randomization (Day 1); Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1)”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Claseprubart on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### EMERGE regimens: 300 mg every 2 weeks or every 4 weeks

> “Following an initial loading dose, claseprubart 300mg/2mL will be administered every two or four weeks (Q2W or Q4W) via subcutaneous (S.C.) injection.”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

> “Experimental: Claseprubart Q2W IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8).”
> “Experimental: Claseprubart Every 4 weeks (Q4W) IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart or Placebo Q2W starting at Week 1 (Day 8), with doses alternating between claseprubart and placebo.”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.10.1-2"></a>

###### MaGic regimens: weight-based loading dose then 300 mg or 600 mg every 2 weeks

> “Dosing: 15 or 20mg/kg I.V. Loading Dose followed by 300mg or 600mg S.C. Q2W starting Day 7”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

> “15 mg/kg for 300mg arm and 20 mg/kg for 600mg arm.”

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

> “Day 1: IV loading dose Week 1 to Week 11: Claseprubart administered SC every 2 weeks”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-2.1.2.10.1-3"></a>

###### MaGic open-label extension dose

> “All patients entering the OLE received claseprubart 600mg Q2W for varying periods of time before the OLE dose was unified to 300mg Q2W following RCT analysis.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-2.1.2.10.1-4"></a>

###### Highest loading dose used in phase 2

> “Highest dose used in Phase 2 trial was single I.V. loading dose of 20mg/kg”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Intravenous loading dose followed by subcutaneous injection

> “Claseprubart intravenous (IV) loading dose on Day 1. Claseprubart subcutaneous (SC) once every 2 weeks for up to 13 weeks.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.10.2-2"></a>

###### Prefilled syringe used in the phase 3 EMERGE trial

> “IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8). Drug: Claseprubart IV loading dose on Day 1 Other Names: DNTH103 Combination Product: Claseprubart Prefilled syringe containing claseprubart for SC administration”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.10.2-3"></a>

###### Target presentation: 300 mg/2 mL self-administered autoinjector

> “Targeting convenience of a single, self-administered S.C. 300mg/2mL autoinjector dosed every 2 or 4 weeks”
> “Autoinjector for claseprubart administration is anticipated to be SHL Medical’s Molly technology, patented or patent pending in the US, China, India, Japan, Korea, Taiwan and at the European Patent Office.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “<10-Second Autoinjector Targeting No Boxed Warning or REMS Self-Administered At Home or On-the-Go”

Source: [Dianthus Therapeutics presentation (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-ex99_1.htm)

<a id="topic-2.1.2.10.2-4"></a>

###### Formulation concentration and viscosity

> “Low volume S.C. delivery Successful manufacturing of 150mg/mL formulation Low viscosity Favorable stability profile DNTH103 Target Product Profile S.C. self-administration 300mg in a 2mL pre-filled auto-injector suitable for convenient, self-administration”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Contract manufacturing: WuXi Biologics

> “We do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We contract with third parties for the manufacture and distribution of our product candidates.”
> “On March 22, 2021, we entered into a biologics master services agreement”
> “manufacturing and testing for claseprubart, as well as potential future candidates, on a work order basis.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-2"></a>

###### Cell line license and royalty on commercial supply from another manufacturer

> “Under the Cell Line License Agreement, we received a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics’ know-how, cell line, biological materials and media and feeds to make, have made, use, sell and import certain drug products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement”
> “Additionally, if we manufacture all of our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics in an amount equal to a fraction of a single digit percentage of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

###### Supply chain contingency: BIOSECURE Act

> “we are strengthening our supply chain in the event that WuXi Biologics or one of our other manufacturers is impacted by the BIOSECURE Act or any similar legislation.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

###### Commercialization plans

> “Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs.”
> “Given the company’s stage of development, we currently do not have a commercial organization for the marketing, sales and distribution of pharmaceutical products.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

###### Greater China license: Tenacia Biotechnology

> “We are currently a party to a license agreement with Tenacia Biotechnology (Hong Kong) Co., Limited”
> “for claseprubart, pursuant to which Tenacia has development and commercialization rights in the People’s Republic of China, including Hong Kong, Macau, and Taiwan”
> “On October 21, 2024, Zenas assigned the Zenas License Agreement to its affiliated entity, Zenas BioPharma (HK) Limited”
> “a $2.5 million upfront payment, which was paid to us by Tenacia in October 2024 upon execution of the Tenacia License Agreement; (ii) reimbursement of a portion of certain clinical costs; (iii) development milestones totaling up to $15.0 million; and (iv) royalties on net sales ranging from the mid-single digits to the low teen percentages.”
> “Tenacia is also responsible for paying local development costs in Greater China and a portion of central development costs based on the number of patients enrolled from China in our global Phase 3 studies.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-6"></a>

###### Autoinjector device: SHL Medical Molly technology

> “Autoinjector for claseprubart administration is anticipated to be SHL Medical’s Molly technology, patented or patent pending in the US, China, India, Japan, Korea, Taiwan and at the European Patent Office.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.11-7"></a>

###### Patent protection

> “Patents issuing from these applications covering claseprubart would be expected to expire no earlier than 2043, subject to any disclaimers or extensions.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “claseprubart IP protection expected through at least 2043, excluding extensions”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Medications excluded before randomization in the phase 3 trial

> “Concurrent or previous use of the following medication within the time periods specified below.”
> “Rituximab or other B-cell targeting therapies (ie, inebilizumab) within 6 months (180 days) prior to randomization (Day 1);”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1)”
> “Previous treatment with claseprubart (DNTH103) or participation in a clinical trial with claseprubart.”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.12-2"></a>

###### Required vaccination against encapsulated bacteria in the phase 3 trial

> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and based on vaccine availability”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.12-3"></a>

###### Medications excluded before randomization in the phase 2 trial

> “Concurrent or previous use of the following medication within the time periods specified below.”
> “Rituximab within 6 months (180 days) prior to randomization (Day 1);”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1).”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-2.1.2.12-4"></a>

###### Required meningococcal vaccination in the phase 2 trial

> “Vaccination against N. meningitidis with the quadrivalent meningococcal vaccine, and where available, meningococcal serotype B vaccine within 3 years prior to, or at the time of, initiating study drug.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-2.1.2.12-5"></a>

###### Background immunosuppressive therapy at baseline in the phase 2 trial

| Characteristic | Placebo (N=22) | Claseprubart 300 mg every 2 weeks (N=21) | Claseprubart 600 mg every 2 weeks (N=22) |
| --- | --- | --- | --- |
| Baseline corticosteroid use, n (%) | “19 (86%)” | “17 (81%)” | “20 (91%)” |
| Number of immunosuppressive therapies at baseline: 1, n (%) | “11 (50%)” | “10 (48%)” | “12 (55%)” |
| Number of immunosuppressive therapies at baseline: more than 1, n (%) | “11 (50%)” | “11 (52%)” | “10 (45%)” |
| Neonatal Fc receptor blocker use in prior 24 months, n (%) | “0 (0%)” | “1 (5%)” | “0 (0%)” |
| Prior complement inhibitor use, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Prior thymectomy, n (%) | “8 (36%)” | “6 (29%)” | “7 (32%)” |

Source: [Peric et al. (2026c)](https://investor.dianthustx.com/static-files/e11cda18-07b8-402e-b329-145717e8dc9b)

<a id="topic-2.1.2.12-6"></a>

###### Rescue therapy and acetylcholinesterase inhibitor use in the phase 2 trial

> “During the RCT period two claseprubart patients received rescue treatment for the exacerbation and one patient had MG worsening attributed to missed pyridostigmine doses on the first day of claseprubart dosing (Day 1).”
> “During the OLE six patients received rescue therapy for the exacerbation.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Claseprubart on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Claseprubart: mechanism, route, dosing interval, and approval status

| Attribute | Quoted text |
| --- | --- |
| Approval status | “Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.” |
| Mechanism of action | “potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein” |
| Route and dosing interval | “Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks.” |
| Regimens in the gMG phase 3 trial | “A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL S.C. Q2W and 300mg/2mL S.C. Q4W in gMG patients was initiated in June” |
| Orphan drug designation | “Claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis in May 2026.” |

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

> “IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8).”
> “Prefilled syringe containing claseprubart for SC administration”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.14-2"></a>

###### Complement C5 inhibitor: Soliris

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “SOLIRIS® (eculizumab) injection, for intravenous use” |
| gMG indication | “the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.” |
| Adult dosing and interval in gMG | “900 mg weekly for the first 4 weeks, followed by” |
| Adult dosing and interval in gMG, continued | “1,200 mg every 2 weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

> “Complement inhibitors for the treatment of AChR antibody-positive gMG emerged in 2017 with eculizumab, marketed as Soliris, a recombinant humanized monoclonal antibody against complement protein C5.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.14-3"></a>

###### Complement C5 inhibitor: Ultomiris

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use” |
| gMG indication | “the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.” |
| Mechanism of action | “Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity” |
| Dosing interval | “maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

> “More recently, another C5 inhibitor, ravulizumab, marketed as Ultomiris, was approved by the FDA for the treatment of adult patients with gMG who are AChR antibody positive in 2022.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.14-4"></a>

###### Complement C5 inhibitor: Zilbrysq

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “ZILBRYSQ® (zilucoplan) injection, for subcutaneous use” |
| gMG indication | “ZILBRYSQ is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Zilucoplan binds to the complement protein C5 and inhibits its cleavage to C5a and C5b, preventing the generation of the terminal complement complex, C5b-9.” |
| Dosing interval | “The recommended dosage of ZILBRYSQ is given once daily as a subcutaneous injection and is dependent on actual body weight” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Neonatal Fc receptor blocker: Vyvgart

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “VYVGART® (efgartigimod alfa-fcab) injection, for intravenous use” |
| gMG indication | “VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).” |
| Mechanism of action | “Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing and interval | “The recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.” |
| Treatment cycles | “Administer subsequent treatment cycles based on clinical evaluation.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2021” |

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Neonatal Fc receptor blocker: Vyvgart Hytrulo

| Attribute | Prescribing information |
| --- | --- |
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| gMG indication | “generalized myasthenia gravis (gMG)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| gMG dosing interval | “Administer in cycles of once weekly injections for 4 weeks.” |
| gMG dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Neonatal Fc receptor blocker: Rystiggo

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “RYSTIGGO® (rozanolixizumab-noli) injection, for subcutaneous use” |
| gMG indication | “RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “Rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing interval | “The recommended dosage is administered as a subcutaneous infusion once weekly for 6 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Neonatal Fc receptor blocker: Imaavy

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “IMAAVY® (nipocalimab-aahu) injection, for intravenous use” |
| gMG indication | “generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.” |
| Dosing and interval | “gMG: The recommended initial dosage is 30 mg/kg once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage, administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes, and continue every two weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2025” |

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### CD19-directed B-cell depleting antibody: Uplizna

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “UPLIZNA® (inebilizumab-cdon) injection, for intravenous use” |
| gMG indication | “Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “The mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD, IgG4-RD, and gMG is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes.” |
| Initial dosing | “Initial dose: 300 mg intravenous infusion followed two weeks later by a second 300 mg intravenous infusion.” |
| Dosing interval | “Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2020” |

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: autoantibody-mediated disorder of neuromuscular transmission

> “Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction.”
> “MG is considered a classic example of antibody-mediated autoimmune disease.”
> “These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane.”
> “Localized or general muscle weakness is the predominant symptom and is induced by the antibodies.”
> “Patients are grouped according to the presence of antibodies, symptoms, age at onset and thymus pathology.”

Source: [Gilhus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31048702/)

<a id="topic-2.2.1.1-2"></a>

###### Generalized and ocular forms

> “MG presents in two forms: ocular (oMG), affecting the levator palpebrae superioris, orbicularis oculi, and extraocular muscles, and generalized (gMG), involving bulbar, axial, limb, and respiratory muscles”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

> “Most patients have generalized weakness affecting the extraocular, bulbar, trunk, and extremity muscles.”
> “In 20% of MG patients, the muscle weakness remains confined to the extraocular muscles”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “It is the prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine receptor (AChR) leading to characteristic fatigable weakness of the ocular, bulbar, respiratory, axial, and limb muscles.”

Source: [Hehir and Silvestri (2018)](https://pubmed.ncbi.nlm.nih.gov/29655448/)

<a id="topic-2.2.1.1-3"></a>

###### Etiology: autoantibody subgroups

> “Antibodies against the AChR are found in approximately 80% of MG patients.”
> “AChR antibodies are predominantly of the IgG1 and IgG3 subclasses”
> “Antibodies against MuSK are found in approximately 7–10% of all MG patients and up to 40% of patients with generalized MG who are seronegative for AChR Abs.”
> “Lrp4 antibodies are present in 2–50% of double seronegative MG cases”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “In around 10% of patients with generalized MG, no antibodies are detected by standard testing.”
> “Many of these patients have low‐concentration or low‐affinity AChR antibodies when tested with more sensitive methods”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.1-4"></a>

###### Etiology: thymus pathology and age at onset

> “Most MG patients have pathogenic autoantibodies against the extracellular part of acetylcholine receptors (AChR), commonly associated with an abnormal thymus.”
> “Thymoma is present in 10% of such patients, and thymic hyperplasia with ectopic germinal centers appears in most patients with symptom onset before age 50 years”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Early-onset MG (EOMG) corresponds to patients presenting before age 50.”
> “Late-onset MG (LOMG) is defined by onset after the age of 50.”
> “MG is the most common paraneoplastic disorder associated with thymoma.”
> “Conversely, 10–20% of patients with MG have thymomas”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.1-5"></a>

###### Etiology: genetic susceptibility

> “There is frequent association of A1-B8-DR3 haplotype with early-onset MG”
> “A large genome-wide association study involving patients from North America and Italy identified different haplotypes across the HLA region, cytotoxic T-lymphocyte-associated protein 4 gene (CTLA4) and tumor necrosis factor receptor 4 superfamily, member 11a, (TNFRSF11A) and NFκB activator genes in early- and late-onset MG cases”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Generalized myasthenia gravis

<a id="topic-2.2.1.2.1-1"></a>

###### United States, 2021 claims and electronic health records: incidence of all myasthenia gravis

> “Data were extracted from the Clarivate Real-World Data Repository (2016-2021), a US claims and electronic health records database.”
> “The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.”
> “While the incidence and prevalence of MG increased with age in both men and women, higher prevalence and incidence of MG were observed in younger women (<50 years) compared with men of matching age, and in older men (≥65 years) compared with women of the same age group.”

Source: [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States, 2017 commercial, Medicare, and Medicaid claims: incidence of all myasthenia gravis

> “From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.”
> “Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.”
> “We extrapolated this to calculate the overall US prevalence of 320.2 per million people and an incidence of 54 per million person-years.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/)

<a id="topic-2.2.1.2.1-3"></a>

###### United States, Medicare fee-for-service beneficiaries aged 65 years and older: incidence of all myasthenia gravis, 2008 to 2019

> “Study-eligible beneficiaries were aged 65 years and older, had at least 1 month of FFS Part A/B coverage, and were without any health maintenance organization insurance coverage.”
> “MG incidence increased from 12.2 to 13.3 per 100,000 PYs from 2008–2009 to 2018–2019 (p < 0.05).”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

<a id="topic-2.2.1.2.1-4"></a>

###### Taiwan, 2009 to 2019: incidence of generalized myasthenia gravis

> “There was no temporal trend in all-cause fatality rates (range 2.76–3.79/100 patients annually) or gMG incidence rates (2.4–3.17/100,000 population annually).”
> “In 2019, the annual prevalence of gMG was 11.18 per 100,000 population and the incidence rate was 2.95 per 100,000 population.”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.2.1-5"></a>

###### Canada, Ontario, 2013 to 2020: incidence of all myasthenia gravis

> “Standardized incidence remained stable (3.2–4.0 per 100,000), while prevalence increased from 36 to 42 per 100,000 from 2013/14 to 2019/20.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.2.1-6"></a>

###### Global systematic review of studies through February 2024: incidence of all myasthenia gravis

> “Incidence rates ranged from 2.3 to 61.3 cases per million person-years, with a mean incidence of 15.7 (95% CI: 11.5–19.9) and a median of 13.3 cases.”
> “Studies showed increasing rates over the years (Fig. 4): considering the period 1967–2007, the mean IR was 8.7 (95% CI: 5.5–11.9; range: 2.3–21.3) cases per million person-years, and in the period 2008–2022, the mean IR has more than doubled: 22.9 (95% CI: 14.1–31.7; range: 6.3–61.3).”
> “The American countries showed the highest mean IR cases per million person-years with a value of 23.7 (95% CI: 6.5–40.9; range: 4.7–61.3).”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

<a id="topic-2.2.1.2.1-7"></a>

###### Global systematic review of studies from 1950 to 2007: pooled incidence of all and AChR antibody-positive myasthenia gravis

> “55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years.”
> “IR ranged from 1.7 to 21.3 cases per million person-years”
> “Pooled estimate IR (eIR) was calculated as 5.3 per million person-years (C.I.: 4.41 - 6.12).”
> “AChR MG IR ranged from 4.3 to 18.0 per million person-years with a pooled AChR MG eIR of 7.3 per million person-years (C.I.: 5.5, 7.8).”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Generalized myasthenia gravis

<a id="topic-2.2.1.2.2-1"></a>

###### United States, 2021 claims and electronic health records: diagnosed prevalence of all myasthenia gravis

> “The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.”
> “The updated prevalence and incidence of MG in the United States in 2021 are higher than previous reports from the 1980s and early 2000s, following a global trend of increased prevalence and incidence for this disorder in the last few decades.”

Source: [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States, 2017 claims and 2021 extrapolation: prevalence and number of adults with all myasthenia gravis

> “Using a previously validated algorithm, we identified cases of MG in two Truven Health MarketScan databases, which during 2017 included a sample of approximately 20 million commercially insured and Medicare recipients, plus 10 million Medicaid recipients.”
> “From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.”
> “Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.”
> “Given our results, we were able to estimate that there were approximately 82,715 US adults living with MG in 2021 (or an estimated 320.2 cases per million adults in the USA).”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States, Medicare fee-for-service beneficiaries aged 65 years and older: prevalence of all myasthenia gravis, 2006 to 2019

> “The period prevalence of MG increased from 81 to 119 per 100,000 FFS A/B population from 2006–2007 to 2018–2019 (p < 0.001).”
> “Increasing trends of prevalence were observed in all sex (male/female), age (65–69/70–74/75–79/80+), race/ethnic (African American/Asian/Hispanics of any race/non-Hispanic White/other), and census region (Northeast/Midwest/South/West) subgroups.”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

<a id="topic-2.2.1.2.2-4"></a>

###### Global meta-analysis of 63 studies: prevalence of all myasthenia gravis

> “After deleting articles unrelated to the research question, finally, 63 articles with a sample size of 1,206,961,907 people were included in the meta-analysis.”
> “The prevalence of MG worldwide was estimated to be 12.4 people (95% CI 10.6–14.5) per 100,000 population.”
> “which has the highest prevalence in the Americas with 19 people (95% CI 15–23.8)”

Source: [Salari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8686543/)

<a id="topic-2.2.1.2.2-5"></a>

###### Global systematic review of studies through February 2024: prevalence of all myasthenia gravis

> “Prevalence of MG ranged from 20 to 475 cases per million, with a mean prevalence of 173.3 (95% confidence interval [CI]: 129.7–215.5) cases per million and a median prevalence of 129.6 cases per million.”
> “The mean PR was 97.5 (95% CI: 59.9–141.9; range: 20–174.2) cases per million considering studies from 1952 to 2007 (the most recent period investigated by the last systematic review [7]), while the mean PR increased up to 220.1 (95% CI: 149.3–288.1; range: 78–475) cases per million considering the period 2008–2021.”
> “North America showed a mean PR of 341.4 (range: 142–475) cases per million”
> “Most of the included studies (81.9%) examined all types of MG (ALL MG), reporting prevalence (59 studies), incidence (50 studies), and mortality (16 studies).”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

<a id="topic-2.2.1.2.2-6"></a>

###### Global systematic review of studies from 1950 to 2007: pooled prevalence of all myasthenia gravis

> “The observed PR ranged from 15 to 179 per million”
> “The estimated pooled PR is 77.7 cases per million (C.I.: 63.98, 94.30) but, as for IR there was marked heterogeneity with I2 = 98% (C.I.: 97-98%) observed across studies limiting interpretation.”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

<a id="topic-2.2.1.2.2-7"></a>

###### Taiwan, 2009 to 2019: prevalence of generalized myasthenia gravis

> “The number of patients with gMG increased from 1,576 in 2009 to 2,638 in 2019 and the mean (standard deviation) age from 51.63 (17.32) to 55.38 (16.29) years.”
> “The prevalence of patients with gMG increased annually from 6.83/100,000 population in 2009 to 11.18/100,000 population in 2019 (p < 0.0001).”
> “The total number of patients with MG (ocular or generalized) increased from 3,647 in 2009 to 6,293 in 2019, with prevalence rates that increased annually from 15.80 per 100,000 population to 26.67 per 100,000 population, a 1.7-fold increase over the study period”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.2.2-8"></a>

###### Canada, Ontario, 2013 to 2020: prevalence of all myasthenia gravis

> “MG prevalence increased from 36 to 42 per 100,000 over the study period.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Natural history: progression from ocular to generalized disease

> “In addition, up to 80% of patients with ocular onset will go on to develop generalized symptoms, usually within two years of disease onset”
> “A recent population-based study conducted by the Mayo Clinic found that 51% of patients presented with ocular onset, and 55% of these developed generalized symptoms”
> “Of the remaining, 90% will continue to have ocular manifestations only.”
> “Hence, ocular MG is defined by isolated extra-ocular involvement for a period of ≥2 years.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Most patients initially present with ocular symptoms, however approximately 80% progress to generalized disease”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.3-2"></a>

###### Natural history: severity peaks early, and exacerbations recur

> “Between 1940 and 2000 a total of 1976 patients with myasthenia gravis (MG) were studied.”
> “The most severe level of weakness and high mortality occurred during the first 1 to 2 years of the disease, after which many patients experienced improvement.”

Source: [Grob et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18059039/)

> “Most patients with MG will experience at least 1 exacerbation of symptoms throughout the course of their illness.”

Source: [Hehir and Silvestri (2018)](https://pubmed.ncbi.nlm.nih.gov/29655448/)

> “Within any given year, approximately one third of patients with gMG experience myasthenic exacerbations (MEs), which are periods when muscle weakness worsens beyond the patient's usual symptoms level”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.3-3"></a>

###### Natural history: spontaneous remission

> “Spontaneous remissions for different lengths of time may occur in the course of adult-onset MG.”
> “In an earlier study conducted before the widespread use of steroids and other immunosuppressants, approximately one fourth of the patients had a complete or near complete spontaneous remission, lasting an average of 4.6 years and up to 17 years”
> “Half of the remissions occurred during the first year after onset.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.3-4"></a>

###### Mortality: global systematic review

> “showing a mean MR of 1.4 (95% CI: 0.8–2.1; range: 0.5–3.5) cases per million person-years.”
> “No trend was observed for MR over the years”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

> “MR range 0.1 to 0.9 per millions person-years.”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

<a id="topic-2.2.1.3-5"></a>

###### Mortality: United States hospitalizations, 2010 to 2019

> “Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.”
> “Mortality among patients aged 65 years or older was higher compared with that in all patients, averaging 5.0% across each of the study years.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.3-6"></a>

###### Mortality: United States hospitalizations, 2000 to 2005

> “The overall in-hospital mortality rate was 2.2%, being higher in MG crisis (4.47%).”
> “Older age and respiratory failure were the predictors of death, with adjusted odds ratios of 9.28 (95% confidence interval [CI], 3.31, 26.0) and 3.58 (95% CI, 2.01, 6.38).”

Source: [Alshekhlee et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19414721/)

<a id="topic-2.2.1.3-7"></a>

###### Mortality and survival: United States Medicare beneficiaries aged 65 years and older

> “All-cause mortality among MG beneficiaries was stable from 6.26 deaths per 100 PYs in 2006–2007 to 5.67 in 2018–2019 (p = 0.18).”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

> “Cohorts of 6024 incident MG and 30,083 control beneficiaries were Included.”
> “The mortality rate was higher in the MG cohort compared to controls (66.8 vs. 57.1 per 1000-person-year, p < 0.0001).”
> “After adjusting for time-varying CCI, no significant difference in survival was observed between two cohorts (adjusted hazard ratio 1.09 [0.87-1.36], p = 0.47).”
> “Sixteen percent of deaths in the MG cohort were attributed to MG.”
> “Compared to the non-MG cohort, mortality rates (per 1000-person-year) specific to infections were higher among the MG cohort (2.0 vs. 1.2) while malignancies and dementia-specific mortality rates were lower (10.3 vs. 12.5 and 4.7 vs. 7.2), all p < 0.01.”

Source: [Li et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41104507/)

<a id="topic-2.2.1.3-8"></a>

###### Mortality: Denmark nationwide cohort, 1985 to 2020

> “Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years.”
> “Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5).”
> “Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population.”

Source: [Jul Jarbæk Nielsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40460351/)

<a id="topic-2.2.1.3-9"></a>

###### Mortality: Taiwan, generalized myasthenia gravis, 2009 to 2019

> “The all-cause fatality rate ranged from 2.76 to 3.79 per 100 patients in each study year, with no consistent temporal trend observed.”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.3-10"></a>

###### Survival: Ontario, Canada, with and without myasthenic crisis

> “Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%.”
> “5‐year overall survival was 75%, declining to 39% among those with crisis.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.3-11"></a>

###### Mortality: Israel, tertiary center cohort, 2000 to 2023

> “Myasthenia Gravis mortality was 14% at 5 years (61/422) and 21% at 10 years (87/422).”
> “Mortality was significantly higher than control groups (p < 0.001).”
> “Intubations during myasthenic crisis were linked to higher mortality (p = 0.002).”

Source: [Khateb et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12116355/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Neuromuscular junction: reduced acetylcholine receptors and sodium channels

> “In addition, there is a reduction in the number of AChRs and voltage-gated sodium channels as the result of complement-related injury to the postsynaptic membrane in MG.”
> “The resultant inefficient neuromuscular transmission is reflected in decremental response in the amplitude of compound muscle action potential (CMAP) during repetitive nerve stimulation (RNS) and abnormal jitter or blocking in single fiber EMG”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.4-2"></a>

###### AChR antibodies: complement fixation, antigenic modulation, and receptor blockade

> “The predominant mechanism is the binding of the antibody and activation of the complement cascade, leading to the formation of the membrane attack complex (MAC), which causes damage of the postsynaptic membrane and destruction of synaptic folds which contain AChRs and associated proteins, including voltage-gated sodium channels”
> “Other mechanisms of pathogenicity include: (1) antigenic modulation by the binding and crosslinking of AChRs, leading to increased endocytosis and degradation [37]; and (2) the impairment of AChR function, either by the blocking of ACh binding to the receptor [38] or the prevention of channel opening”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Anti-AChR autoantibodies belong to the IgG1 and IgG3 subclasses, that are the strongest activators of the complement system.”
> “Indeed, pathogenicity of these autoantibodies, but not that of anti-MuSK antibodies that belong to IgG4, is mainly due to complement fixation at the NMJ ultimately leading to postsynaptic membrane destruction and impairment of the neuromuscular transmission”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

<a id="topic-2.2.1.4-3"></a>

###### Complement: classical pathway initiation at the endplate

> “In MG, complement-mediated damage of the NMJ occurs via the classical complement pathway, which starts with C1q binding to the Fc domain of the autoantibodies.”
> “Critical steps of the complement cascade are then the cleavage of C3 into C3a and C3b, and of C5 in C5a and C5b, the latter leading to the formation of the membrane attack complex (MAC, C5bC6C7C8C9 also known as C5b-9) that causes focal lysis of the post-synaptic membrane, disruption of post-junctional folds, and ultimately reduction of functional AChRs”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “In MG, the classical pathway is involved by the initiation of the antigen/antibody complex being recognized by C1q.”
> “The C1q forms a pentameric complex with the C1r2C1s2 serine protease tetramer.”
> “C2 also becomes cleaved by C1s to form the C3 convertase (C4b2a).”

Source: [Kusner et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3531867/)

<a id="topic-2.2.1.4-4"></a>

###### Complement: deposition at the endplate in patients

> “In muscle biopsies from MG patients, IgG and C3 deposition was localized at identical sites of post-synaptic membrane, and specifically on debris of junctional folds in the synaptic clefts and disintegrating junctional folds”
> “Deposition of C9, the main component of the final and stable MAC, was also observed at the MG end plate regions, with the most intense depositions associated with the destroyed NMJs, indicating that NMJ loss may be largely due to complement activation”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “Patients with anti-AChR+ MG have autoantibodies and MACs present at NMJs.”
> “Damaged NMJs are associated with more severe disease, fewer AChRs, and MACs in synaptic debris.”

Source: [Howard (2018)](https://pubmed.ncbi.nlm.nih.gov/29266249/)

<a id="topic-2.2.1.4-5"></a>

###### Complement: evidence from experimental autoimmune myasthenia gravis

> “Mice deficient in C3 and C4 demonstrate reduced clinical scores compared to their wild-type littermates during the course of active EAMG, with C3-knockout mice showing no signs of weakness.”
> “Complement-deficient EAMG animals showed a preservation of AChR density at the neuromuscular junction.”
> “C5-deficient mice demonstrated reduced incidence of disease compared to the C5-sufficient mice.”

Source: [Kusner et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3531867/)

> “Studies in animals lacking specific complement proteins have confirmed that MAC formation is required to induce experimental autoimmune MG (EAMG) and NMJ damage.”
> “Complement inhibition in EAMG models can prevent disease induction and reverse its progression.”

Source: [Howard (2018)](https://pubmed.ncbi.nlm.nih.gov/29266249/)

<a id="topic-2.2.1.4-6"></a>

###### Complement: C1s and classical pathway activation in patients

> “The C1-inhibitor (C1-INH) regulates the classical pathway and is a promising marker in other autoimmune disorders.”
> “Serum and plasma C1s-C1-INH levels were higher in MG patients than in matched healthy controls, supporting early classical pathway activation in most MG patients.”
> “These findings allow prospective validation studies of activated C1s as a putative treatment target and potential accompanying biomarker in MG.”

Source: [Huang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255718/)

> “Circulating complement protein profile may be used as a biomarker for evaluating patient-specific complement activation: (i) Romi and colleagues found reduced C3 and C4 serum levels in AChR-MG patients with high autoantibody titers, indicating increased in vivo complement consumption”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

<a id="topic-2.2.1.4-7"></a>

###### Complement: heterogeneity of complement dependence and response to C5 inhibition

> “By means of this system, they observed a subset of AChR-MG patients with high complement activity, who are likely patients in whom complement activation is the major disease mechanism, whereas the remaining patients showed low activity, reflecting possible complement-independent autoantibody-mediated mechanisms of NMJ damage”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.”
> “It is important to note that in MG there is no evidence suggesting a role for C5a in the disease.”
> “There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.1.4-8"></a>

###### MuSK and LRP4 antibodies: complement-independent mechanisms

> “MuSK antibodies belong mainly to the IgG4 subclass.”
> “They do not fix complement and are not strong activators of cell-mediated cytotoxicity”
> “The mechanism by which MuSK antibodies exert their pathogenic effect on the neuromuscular junction is via binding to the Ig-like domain of the protein, preventing its phosphorylation, and subsequently disrupting the Agrin-Lrp4-MuSK-Dok-7 signaling pathway.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “The LRP4 antibodies are primarily IgG1 and IgG2 subtypes and follow similar clinical presentation to a mild form of early-onset MG (22), inhibit clustering of AChR, and appear not to strongly activate complement”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Clinical diagnosis and confirmatory testing

> “The diagnosis of autoimmune Myasthenia Gravis (MG) remains clinical and rests on the history and physical findings of fatigable, fluctuating muscle weakness in a specific distribution.”
> “Ancillary bedside tests and laboratory methods help confirm the synaptic disorder, define its type and severity, classify MG according to the causative antibodies, and assess the effect of treatment objectively.”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

> “Diagnosis is straightforward in most patients with typical symptoms and a positive antibody test, although a detailed clinical and neurophysiological examination is important in antibody-negative patients.”

Source: [Gilhus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31048702/)

<a id="topic-2.2.1.5-2"></a>

###### Antibody testing: AChR antibodies

> “In a patient with clinical features of MG, serum testing for AChR-Ab is the first recommended step in diagnosis by most recent guidelines and expert opinions”
> “The test has a very high specificity, so the detection of elevated titers in the appropriate clinical setting is diagnostic of AChR-myasthenia, and further testing may not be necessary”
> “The RIPA for binding Ab is abnormal in up to 85% of adult patients with generalized MG, but only about 50% of patients with ocular MG”
> “The technique detects autoantibodies to clustered AChR in about 15% of RIPA-seronegative MG patients”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-3"></a>

###### Antibody testing: MuSK and LRP4 antibodies and seronegative disease

> “MuSK-Ab are found in about 6–8% of all MG cases”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

> “In approximately 15% of patients with generalized MG and 50% of patients with ocular MG, both AChR and MuSK antibodies were absent.”
> “Detection rates in double-seronegative patients range from 2% to 50%, depending on the geographical origin, with LRP4-Ab being more frequent in non-Caucasian patients, and on the employed assay, with Live CBA being the most widely used”

Source: [Vinciguerra et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526522/)

<a id="topic-2.2.1.5-4"></a>

###### Antibody testing: United States testing patterns after a new diagnosis

> “Of 5788 cases, 2590 (44.7 %) had at least one valid serology test result: 1453 (56.3 %) seronegative, 1094 (42.4 %) anti-AChR+, 28 (1.1 %) anti-MuSK+, and 5 (0.2 %) anti-LRP4+.”
> “Among the seronegative, 56.6 % were only tested for anti-AChR antibodies, 33.7 % tested both anti-AChR and anti-MuSK antibodies, and 5.0 % tested all three antibodies.”

Source: [Pesa et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41455461/)

<a id="topic-2.2.1.5-5"></a>

###### Electrodiagnosis: repetitive nerve stimulation

> “In generalized MG, RNS of distal muscles is abnormal in 30–35% of patients, while in proximal muscles, it is abnormal 60–70%”
> “One should note as a standard feature the high specificity of RNS, which reaches about 97% in generalized MG and 94% in ocular MG”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-6"></a>

###### Electrodiagnosis: single-fiber and concentric needle jitter

> “The jitter study is the most sensitive indicator of impaired neuromuscular transmission”
> “The CNE jitter is abnormal in 98–100% in generalized MG and above 90% in ocular MG.”
> “While highest in sensitivity, jitter measurements are not specific and may be abnormal in other synaptic disorders, in denervation and reinnervation processes (poly- and mononeuropathies), some myopathies, and with motor neuron disorder (MND) in particular”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-7"></a>

###### Bedside tests: ice-pack and edrophonium tests

> “The test is used mostly in ocular MG and seems more popular among neuro-ophthalmologists; some authors report sensitivities equal to that of single-fiber electromyography (SFEMG) in patients presenting with ptosis and a very high negative predictive value”
> “However, others note much lower specificity at about 25%”
> “In the USA, edrophonium has been discontinued since 2018”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-8"></a>

###### MGFA clinical classification

| Class | Quoted definition |
| --- | --- |
| Class I | “Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal.” |
| Class II | “Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class IIa | “Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.” |
| Class IIb | “Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.” |
| Class III | “Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class IV | “Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class V | “Defined as intubation, with or without mechanical ventilation, except when employed during routine postoperative management. The use of a feeding tube without intubation places the patient in class IVb.” |

Source: [Myasthenia Gravis Foundation of America](https://myasthenia.org/wp-content/uploads/Portals/0/MGFA%20Classification.pdf)

<a id="topic-2.2.1.5-9"></a>

###### Consensus definitions: treatment goal, remission, crisis, and refractory disease

> “MMS: The patient has no symptoms or functional limitations from MG but has some weakness on examination of some muscles.”
> “Rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks).”
> “Worsening of myasthenic weakness requiring intubation or noninvasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management”
> “PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.1.5-10"></a>

###### Diagnostic delay: United States patients with generalized myasthenia gravis

> “Quantitative surveys and qualitative interviews were conducted (January-May 2023) in patients with gMG (n = 71 surveys; n = 47 interviews) and clinicians in the United States treating patients with gMG (n = 12 surveys and interviews).”
> “Patients had mean (SD) diagnostic journey time of 11.8 (22.5) months from symptom onset to seeking care and 15.5 (36.7) months from seeking care to diagnosis.”
> “Sources of diagnostic journey delay (≥9.9 % patients) were: clinicians mistaking gMG symptoms as female health issues, difficulty accessing specialty care, and lack of gMG knowledge among HCPs.”

Source: [Jiang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41319378/)

Additional sources: [Jaretzki et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10891897/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Core feature: fatigable, fluctuating, predominantly proximal weakness

> “The core clinical manifestation of MG is fatigable muscle weakness, worsened by exertion and improved by rest.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Muscle weakness fluctuates over time and increases with repeated or sustained muscle use.”
> “The weakness is more pronounced in proximal than distal muscles, and leg muscles are typically mildly weak or unaffected.”
> “The weakness is symmetrical, apart from the eyes.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Nearly all participants (96%) reported fluctuations in symptoms and severity.”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

<a id="topic-2.2.1.6-2"></a>

###### Ocular symptoms: ptosis and diplopia

> “The most common presenting symptoms are ocular, with double vision and ptosis.”
> “Most patients will develop diplopia and/or ptosis some time during the course of their disease.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-3"></a>

###### Bulbar symptoms: dysarthria, dysphagia, and facial and jaw weakness

> “Bulbar muscles are also frequently involved, resulting in flaccid dysarthria, dysphagia, and facial and jaw weakness”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Generalized MG (gMG) involves multiple muscle groups, including limb, axial, and bulbar muscles, and can present with difficulty chewing, talking, swallowing, or breathing”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.6-4"></a>

###### Axial symptoms: neck weakness and head drop

> “Axial weakness can also be present, with neck flexion weakness usually more common than weakness of neck extension.”
> “In a previous retrospective study from our center, about 10% of MG patients developed head-drop some time during the disease course”
> “Head-drop was associated with age >60 and male patients in that study.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-5"></a>

###### Limb symptoms: proximal and, less often, distal weakness

> “Limb muscle weakness tends to be symmetric and proximal, and patients commonly complain of difficulty climbing stairs, getting up from chairs, and raising arms above their head.”
> “In some instances, distal muscles can be predominantly affected, either in a symmetric or asymmetric distribution.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-6"></a>

###### Respiratory symptoms: respiratory muscle weakness

> “Finally, 15–20% of patients with AChR-MG can develop respiratory weakness requiring mechanical ventilation (MG crisis)”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-7"></a>

###### Patient-reported symptoms: frequency and most bothersome symptoms

> “Semi-structured, in-depth concept-elicitation interviews were conducted with 28 individuals diagnosed with gMG in the United States.”
> “Participants reported gMG symptoms that affected many body regions and functions, with an average of 16 symptoms per participant.”
> “The most frequently reported symptoms were eyelid drooping (93%), physical fatigue (89%), symptoms affecting the legs (82%), difficulty breathing (82%), and difficulty holding head up (82%).”
> “Participants’ most bothersome symptoms were blurry/double vision (43%), breathing difficulties (36%), all-over fatigue (36%), and swallowing problems (29%).”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

<a id="topic-2.2.1.6-8"></a>

###### Fatigue and emotional symptoms

> “All participants reported emotional impacts and impacts on their work and finances.”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

> “Even patients with only mild symptoms have a decreased quality of life because of fatigue, treatment side effects, and worries about exacerbations and complications”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.6-9"></a>

###### Symptoms by antibody subgroup: MuSK antibody-positive disease

> “Muscle weakness preferentially affects cranial and bulbar muscles.”
> “Over 40% of patients present with bulbar weakness, usually associated with neck and respiratory involvement”
> “About 30% of patients present with diplopia and/or ptosis.”
> “Limb weakness can be uncommon, but when present it tends to be severe and associated with muscle atrophy.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Myasthenic crisis: frequency, triggers, and outcomes

> “Myasthenic crisis (MC) is a life-threatening manifestation of myasthenia gravis (MG) defined by respiratory insufficiency that requires the use of invasive or non-invasive ventilation.”
> “MC occurs in approximately 15%-20% of patients with MG usually within the first 2 to 3 y of the disease course.”
> “Many crises have a specific trigger with respiratory infections being most common; however, no specific trigger is found in 30%-40% of patients.”
> “MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk.”
> “The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities.”

Source: [Claytor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37114503/)

> “A myasthenic crisis (MC) is a more severe, life-threatening escalation of muscle weakness that leads to respiratory failure, necessitating intensive care unit admission with assisted ventilation, usually requiring an inpatient stay period of several weeks, often in the range of 2–4 weeks”
> “Approximately 20% of patients with gMG are estimated to experience MC during a period of 3 years or longer”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.7-2"></a>

###### Myasthenic crisis: Ontario, Canada, population-based incidence

> “Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.7-3"></a>

###### Exacerbations and crises: predictors and inpatient use, United States generalized myasthenia gravis

> “Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).”
> “After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index.”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.7-4"></a>

###### Hospitalization trends: United States, 2010 to 2019

> “Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001).”
> “The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.7-5"></a>

###### Refractory disease: persistent moderate or severe weakness

> “However, 10%–20% of patients continue to have long‐standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.7-6"></a>

###### Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis

> “Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).”
> “During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001”
> “Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).”
> “Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)”
> “Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.”
> “Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="topic-2.2.1.7-7"></a>

###### Glucocorticoid toxicity: recognized adverse effects and higher-risk patients

> “However, long-term use of GCs is associated with potentially serious toxicities, including weight gain, cataracts, hypertension, diabetes, osteoporosis, infections, and neuropsychiatric symptoms”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

> “MG patients with osteoporosis, obesity, diabetes, and mental disorders have a particularly high risk of corticosteroid side effects.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Generalized myasthenia gravis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Patient-reported burden by MGFA class: MyRealWorld MG baseline, seven countries

> “Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG.”
> “Baseline results of 841 participants (mean age 47 years, 70% women) are reported.”
> “The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision.”
> “Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV.”
> “MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.”

Source: [Dewilde et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890761/)

<a id="topic-2.2.1.8.1-2"></a>

###### Health utilities and medical care use compared with the general population

> “In MRW ( n = 1859), 58.4% of respondents had moderate-to-severe MG. Average utility values were lower in MRW versus POPUP (0.739 vs. 0.843 for EQ-5D-5L; 0.493 vs. 0.746 for HUI3), and declined with more severe disease (0.872, 0.707, 0.511 EQ-5D-5L utilities and 0.695, 0.443, 0.168 HUI3 utilities for mild, moderate, and severe MG, respectively).”
> “Use of medical care was twice as likely in MRW in comparison with POPUP (51.9% vs. 24.6%).”

Source: [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/)

<a id="topic-2.2.1.8.1-3"></a>

###### Quality of life and support needs in U.S. adults receiving standard of care without advanced biologics

> “Patients had received treatment with standard of care (acetylcholinesterase inhibitors, non-steroidal immunosuppressants, corticosteroids, rituximab, immunoglobulins, plasmapheresis) but not advanced biologics (eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, nipocalimab).”
> “Overall, 157 eligible patients completed the survey (87.3% female, mean [SD] age 49.5 [14.4] years, mean [SD] time since diagnosis 11.0 [10.9] years). Mean (SD) MG-QoL-15R score was 16.2 (7.2), EQ5D-5L score was 0.6 (0.3), and FACIT-fatigue subscale score was 20.2 (11.3). Overall, 51.6% received additional support/care.”
> “Patients with moderate/severe gMG (136/157 [86.6%]) had greater symptom occurence, reduced treatment satisfaction, greater health-related quality of life impairment, and greater support/care needs, compared with patients with mild gMG.”

Source: [Pesa et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/43001852/)

<a id="topic-2.2.1.8.1-4"></a>

###### Life domains affected in U.S. patients and caregivers

> “across 8 life domains (occupation, financial, emotional, physical, sleep, social, planning and autonomy, and safety)”
> “Respondents included 239 patients with gMG (63%, aged 18–49 y; 69%, female) and 81 caregivers (58%, aged 18–49 y; 42% female).”
> “The 5 domains most impacted by gMG were occupational (mean domain score [SD]: 4.0 [1.2]), planning and autonomy (4.0 [1.1]), financial (3.9 [1.2]), physical (3.9 [1.1]), and sleep (3.9 [1.2]) for patients and financial (3.7 [1.2]), sleep (3.7 [1.1]), occupational (3.6 [1.2]), planning and autonomy (3.6 [1.1]), and safety (3.6 [1.1]) for caregivers.”
> “Eligible patients were aged ≥ 18 years currently living in the United States with a self-reported physician diagnosis of gMG regardless of antibody status.”

Source: [Narayanaswami et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13400517/)

<a id="topic-2.2.1.8.1-5"></a>

###### Systematic review of psychological symptoms and health-related quality of life

> “Sixty-seven publications were included in the SLR. Compared with the general population, patients with MG experienced worse HRQoL.”
> “However, in general those with more severe symptoms and hospitalization days had worse depression and anxiety, and fatigue and sleep improved with disease remission and/or improvement. Scores were worse for females compared with males and where evaluated, HRQoL scores generally improved following treatment.”

Source: [Gelinas et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35486970/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023

> “Adults with newly diagnosed gMG were identified from Komodo Research data (January 1, 2017, to September 30, 2023).”
> “The gMG cohort (mean follow-up = 32.7 months) compared with the non-MG cohort (mean follow-up = 31.3 months) had 2.4, 1.6, and 1.9 times more inpatient days, emergency department visits, and outpatient visits annually, respectively (all P < 0.001).”
> “Mean annual all-cause total health care costs in the gMG cohort were $43,872 higher than in the non-MG cohort ($58,341 vs $14,469; P < 0.001); 59.3% of the difference was driven by pharmacy costs (mostly immunoglobulin).”
> “Prediagnosis weakness and fatigue symptoms, exacerbation or crisis, and use of immunoglobulin were important factors significantly associated with high health care costs in the gMG cohort (all P < 0.001).”

Source: [Grover et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13293495/)

<a id="topic-2.2.1.8.2-2"></a>

###### Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims

> “Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).”
> “After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index. Mean total healthcare costs were $70,792 higher among patients with a clinical event ($95,821 vs. $25,029, p < 0.001), driven by immunoglobulin and inpatient costs.”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.8.2-3"></a>

###### Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023

> “Analyses included 16,561 gMG patients (12,813 prevalent and 3748 incident) and 105,716 non-gMG controls. Among prevalent and incident gMG patients, respectively, MG exacerbation occurred during follow-up in 12.2 and 22.0% and myasthenic crisis in 6.0 and 12.4%.”
> “After weighting, gMG patients (median follow-up 696 days) experienced more frequent all-cause HCRU encounters and >4-fold higher healthcare costs ($5420 PPPM or ∼$65,000 per annum) versus non-gMG controls ($1298 PPPM or ∼$15,500 per annum).”
> “Among MG patients, those with MG exacerbation/myasthenic crisis, respectively, experienced means of 3.02/3.35 hospitalizations, 1.91/2.13 emergency department encounters, 12.70/13.39 skilled nursing facility encounters, and 67.86/75.52 outpatient encounters during follow-up; associated costs were $17,113/$18,640 PPPM (or ∼$205,000/$224,000 per annum).”

Source: [Jackson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41099443/)

<a id="topic-2.2.1.8.2-4"></a>

###### Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021

> “The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient costs of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001.”
> “Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively.”

Source: [Zhdanava et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38745448/)

<a id="topic-2.2.1.8.2-5"></a>

###### First-year costs after diagnosis by payer: U.S. commercial and Medicare claims, 2016 to 2021

> “The final analytic cohort included 3,700 patients with MG and 37,000 controls. On average, patients were aged 54 years, with 60% being female. The difference-in-difference estimates of the total health care cost for MG diagnosis in commercial and Medicare patients were $25,799 and $4,927, respectively (P < 0.01).”

Source: [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039500/)

<a id="topic-2.2.1.8.2-6"></a>

###### Costs in newly diagnosed and previously diagnosed patients and around crisis events: U.S. claims, 2014 to 2019

> “Mean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02).”
> “For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99).”

Source: [Phillips et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8805609/)

<a id="topic-2.2.1.8.2-7"></a>

###### Costs in patients treated with chronic IVIg or multiple nonsteroidal immunosuppressants

> “Compared with the reference cohort (n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg (n = 324) and multiple NSIST (n = 291) cohorts (p < 0.001); and the MG exacerbation rate was approximately four-fold higher in the chronic IVIg cohort (p < 0.001) and three-fold higher in the multiple NSIST cohort (p < 0.001).”
> “Median annual MG-related inflation-adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).”

Source: [Parthan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38018505/)

<a id="topic-2.2.1.8.2-8"></a>

###### Costs by glucocorticoid exposure: U.S. commercial claims

> “Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).”
> “Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%).”
> “Annual all-cause costs were >2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309). GC acute and chronic toxicities and costs tended to increase with increasing GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="topic-2.2.1.8.2-9"></a>

###### Hospitalization trends: U.S. Nationwide Inpatient Sample and Medicare, 2010 to 2019

> “Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001). Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.”
> “The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.8.2-10"></a>

###### Range of direct and indirect costs across studies: systematic reviews

> “Across studies, the mean per-patient annual direct medical cost of illness was estimated at between $760 and $28,780, and cost per hospitalization between $2550 and $164,730. The indirect cost of illness was estimated at $80 and $3550.”
> “Costs varied considerably by patient characteristics, and drivers of the direct medical cost of illness included intravenous immunoglobulin and plasma exchange, myasthenic crisis, mechanical ventilatory support, and hospitalizations.”

Source: [Landfeldt et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32363541/)

> “1374 records were identified initially, and 44 were included in the final review.”
> “Direct costs include treatment and follow-up in the primary and specialist health care. They were estimated to €3 500–12 000 per MG patient per year in the Nordic countries, similar in other European countries, and higher in United States.”
> “Intangible costs include value of lost life-years and reduced quality of life, which are rarely assessed, but have been estimated to be half of the total societal MG costs.”

Source: [Gilhus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13645850/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Generalized myasthenia gravis on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Out-of-pocket costs and financial adjustments reported by U.S. patients and caregivers

> “Eight hundred people with MG and 238 caregivers responding on behalf of a person with MG completed the survey.”
> “70% reported making financial adjustments or seeking financial assistance. Annual out-of-pocket costs (mean, $15,798; median, $7750) were primarily driven by medications, cost to receive a diagnosis, and healthcare insurance premiums. People receiving infusions paid significantly more across all care domains.”

Source: [Yoder et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39697037/)

<a id="topic-2.2.1.8.3-2"></a>

###### Patient and caregiver productivity losses by symptom severity: MyRealWorld MG

> “In the MyRealWorld-MG study, 36.5% of MG patients reported taking sick leave within the last month and 11.4% reported stopping work (or retiring early) due to MG. Furthermore, 36.0% required caregiver support with 14.6% of caregivers reducing working hours and 13.4% stopping work.”
> “Patients with severe MG incurred 3.8 times more productivity losses compared to patients with mild disease.”

Source: [Dewilde et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12062151/)

<a id="topic-2.2.1.8.3-3"></a>

###### Annual productivity losses per patient in the United States by MG-ADL category

| MG-ADL category | Patient productivity losses | Caregiver productivity losses | Grand total |
| --- | --- | --- | --- |
| Mild | “$8,160” | “$1,302” | “$9,462” |
| Moderate | “$9,063” | “$3,541” | “$12,604” |
| Severe | “$10,997” | “$3,791” | “$14,788” |
| All patients | “$9,468” | “$3,141” | “$12,609” |

Source: [Dewilde et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12062151/)

<a id="topic-2.2.1.8.3-4"></a>

###### Caregiver burden measured with the Zarit Burden Interview in five European countries

> “A cross-sectional study design collected patient and caregiver data in Germany, Italy, Spain, the UK, and France.”
> “Caregivers (N = 69) reported a mean ZBI-22 score of 24.3, with 40.6% reporting no burden, 47.8% mild-to-moderate burden, 8.7% moderate-to-severe burden, and 2.9% severe burden.”
> “Informal caregivers of MG patients experience a substantial burden, impacting their physical, emotional, and financial well-being.”

Source: [Dewilde et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12178031/)

<a id="topic-2.2.1.8.3-5"></a>

###### Sick leave and need for caregiver help compared with the general population

> “Taking sick leave in the past month was 2.6 times more frequent among people diagnosed with MG compared to the general population (34.4% vs. 13.2%) and four times more people diagnosed with MG reported needing help from a caregiver (34.8% vs. 8.3%).”

Source: [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/)

<a id="topic-2.2.1.8.3-6"></a>

###### Economic concerns of U.S. adults with gMG facing social determinants of health barriers

> “The survey was completed by 38 individuals living with gMG, the majority of whom were enrolled in public insurance and not employed. The most commonly reported major economic concerns were managing funds for emergency care (66%), loss of income (61%), and non-medical expenses (58%), highlighting the diversity of economic challenges.”

Source: [Hughes et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10520715/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Acetylcholine receptor antibody positivity required for enrollment in the phase 3 trial of claseprubart

> “Diagnosis of gMG by the following tests: Acetylcholine receptor antibody (AChR Ab) positive, and One of the following: i. History of abnormal neuromuscular transmission test; ii. History of positive anticholinesterase test; iii. Clinical response to acetylcholinesterase”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.2.1.8.4-2"></a>

###### Out-of-pocket cost of receiving a diagnosis reported by U.S. patients

> “Demographic disparities were observed, with people of color, women, and those on disability paying significantly more to receive a diagnosis than their counterparts.”

Source: [Yoder et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39697037/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Acetylcholinesterase Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

###### Pyridostigmine as initial symptomatic treatment: international consensus guidance

> “Pyridostigmine should be part of the initial treatment in most patients with MG. Pyridostigmine dose should be adjusted as needed based on symptoms. The ability to discontinue pyridostigmine can be an indicator that the patient has met treatment goals and may guide the tapering of other therapies.”
> “Corticosteroids or IS therapy should be used in all patients with MG who have not met treatment goals after an adequate trial of pyridostigmine.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.1-2"></a>

###### Pyridostigmine dosing, adverse effects, and second-line symptomatic agents: Nordic guidance

> “Pyridostigmine represents the first‐line symptomatic treatment, while ambenonium and beta adrenergic agonists are second‐line options.”
> “Pyridostigmine dosage is titrated individually, where 30–60 mg every 4–6 h is a typical adult dose”
> “In a Dutch–Belgian cohort, 91% reported side effects from pyridostigmine, and one in four discontinued the treatment mainly due to side effects”
> “Pyridostigmine in optimal dose should be given as a first‐line symptomatic treatment in most patients with MG. The optimal dose can vary according to activity needs and be adjusted by the patient accordingly. Terbutaline and salbutamol can be used as adjuvant symptomatic treatments.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.1-3"></a>

###### FDA-labeled indication and dosing: pyridostigmine

> “MESTINON is useful in the treatment of myasthenia gravis.”
> “The size and frequency of the dosage must be adjusted to the needs of the individual patient.”
> “The average dose is ten 60 mg tablets or ten 5 mL teaspoonfuls daily, spaced to provide maximum relief when maximum strength is needed.”

Source: [Mestinon prescribing information (2023)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a851795e-b7a8-40c3-9922-5e79d3eb4d92)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Corticosteroids

<a id="topic-2.2.2.1.2-1"></a>

###### Corticosteroid use and tapering: international consensus guidance

> “Once patients achieve treatment goals, the corticosteroid dose should be gradually tapered. In many patients, continuing a low dose of corticosteroids long-term can help to maintain the treatment goal.”
> “Because corticosteroids may cause transient worsening of myasthenic weakness, it may be appropriate to wait several days for PLEX or IVIg to have a beneficial effect before starting corticosteroids”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.2-2"></a>

###### Corticosteroid dosing and combination with a steroid-sparing agent: Nordic guidance

> “Early high‐dose oral prednisone or prednisolone is recommended (0.75–1.00 mg/kg) in patients with moderate to severe generalized MG”
> “In patients with mild to moderate generalized MG, steroids can be given at lower doses (0.25 mg/kg), followed by gradual escalation depending on the clinical response.”
> “A gradual increase of steroid dose from 5 to 10 mg daily over a few weeks is recommended to avoid an initial worsening.”
> “In 75% of patients, steroids have an effect within 2–4 weeks.”
> “Due to the high risk of long‐term adverse effects and to further improve muscle weakness, corticosteroids should be combined with another immunosuppressive drug.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.2-3"></a>

###### Daily rather than alternate-day dosing: British guideline update

> “The recommendation to prescribe daily steroids rather than the alternate day regimen is now standard practice.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

<a id="topic-2.2.2.1.2-4"></a>

###### Glucocorticoid exposure in US commercially insured adults with generalized myasthenia gravis

> “Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).”
> “Use of nonsteroidal immunosuppressants was higher among patients with GC use than those without (37.6% any GC use vs 19.6% no GC use).”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Nonsteroidal Immunosuppressive Agents

<a id="topic-2.2.2.1.3-1"></a>

###### Indications for and choice of nonsteroidal immunosuppressive agents: international consensus guidance

> “A nonsteroidal IS agent should be used alone when corticosteroids are contraindicated or refused. A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities. A nonsteroidal IS agent should be added to corticosteroids when: a. Steroid side effects, deemed significant by the patient or the treating physician, develop; b. Response to an adequate trial (table e-1) of corticosteroids is inadequate; or c. The corticosteroid dose cannot be reduced due to symptom relapse.”
> “Nonsteroidal IS agents that can be used in MG include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. The following factors should be considered in selecting among these agents: a. There is widespread variation in practice with respect to choice of IS agent since there is little literature comparing them. b. Expert consensus and some RCT evidence support the use of azathioprine as a first-line IS agent in MG. c. Evidence from RCTs supports the use of cyclosporine in MG, but potential serious adverse effects and drug interactions limit its use. d. Although available RCT evidence does not support the use of mycophenolate and tacrolimus in MG, both are widely used, and one or both are recommended in several national MG treatment guidelines”
> “For nonsteroidal IS agents, once treatment goals have been achieved and maintained for 6 months to 2 years, the IS dose should be tapered slowly to the minimal effective amount.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.3-2"></a>

###### Methotrexate as a steroid-sparing agent: 2020 consensus update

> “An RCT enrolled 50 patients with AChR-Ab+ MG taking prednisone at a dose of ≥10 mg/d. 34 Patients were randomized 1:1 to MTX 20 mg/wk or placebo. There was no difference in the primary outcome measure, the area under the prednisone dose-time curve between months 4 and 12, and the mean 12-month change in QMG, MMT, MG-Quality of life, MG-ADL, and MGC was no different between treatment groups.”
> “Although evidence from RCTs is lacking, oral MTX may be considered as a steroid-sparing agent in patients with generalized MG who have not tolerated or responded to steroid-sparing agents that are better supported by RCT data”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.3-3"></a>

###### Azathioprine first choice and onset of effect: Nordic guidance

> “These drugs have a delayed response of 1 to 6 months, and the full effect is sometimes reached after more than 1 year.”
> “In the Nordic countries, azathioprine (2–3 mg/kg) is usually the first‐line treatment in both adults and children. Mycophenolate (1–2 g daily), methotrexate (20 mg/week), and tacrolimus (3 mg daily) are secondary alternatives.”
> “Azathioprine is recommended as the first‐choice non‐steroidal immunosuppressant drug. Mycophenolate, methotrexate, and tacrolimus are recommended as secondary immunosuppressants.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Thymectomy

<a id="topic-2.2.2.1.4-1"></a>

###### Thymectomy in nonthymomatous AChR antibody-positive disease: 2020 consensus update

> “In nonthymomatous, generalized MG patients with AChR-Ab, aged 18–50 years, thymectomy should be considered early in the disease to improve clinical outcomes and to minimize immunotherapy requirements and the need for hospitalizations for disease exacerbations (median 9, range 2–9).”
> “Thymectomy should be strongly considered in patients with AChR-Ab+ generalized MG if they fail to respond to an initial adequate trial of immunotherapy or have intolerable side effects from that therapy”
> “Current evidence does not support an indication for thymectomy in patients with MuSK, low-density lipoprotein receptor–related protein 4, or agrin antibodies”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.4-2"></a>

###### MGTX randomized trial: 3-year results

> “A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in the thymectomy group also had a lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001). Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001).”
> “Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis.”

Source: [Wolfe et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5189669/)

<a id="topic-2.2.2.1.4-3"></a>

###### MGTX extension: 5-year results

> “Of 111 subjects who completed the 3-year MGTX trial, 68 (61%) entered the extension study between September 1, 2009 and August 26, 2015 (33 prednisone alone; 35 prednisone plus thymectomy).”
> “At 5 years, patients randomised to thymectomy plus prednisone continued to demonstrate improved clinical status compared to patients in the prednisone alone group based on time-weighted average QMG (5.47±3.87 vs. 9.34±5.08; 95% CI for the difference 0.71–7.04; p=0.0007) and lower average alternate-day prednisone requirements (24 mg±21 mg vs. 48±29 mg; 95% CI for the difference 12–36 mg; p=0.0002). The proportion of patients requiring hospitalisation for MG exacerbation (6% vs. 30%; 95% CI for the difference 7.1–42.1%; p=0.0105) was lower in the thymectomy group.”

Source: [Wolfe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6774753/)

<a id="topic-2.2.2.1.4-4"></a>

###### AAN practice advisory on thymectomy

> “For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence).”
> “Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B).”

Source: [Gronseth et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32213645/)

<a id="topic-2.2.2.1.4-5"></a>

###### Timing of thymectomy by age: Nordic guidance

> “In patients with non‐thymoma, generalized MG, AChR antibodies, and age below 50 years, thymectomy should be performed within 4 months from diagnosis.”
> “In patients with non‐thymoma generalized MG, AChR antibodies, and age 50–65 years, early thymectomy should be considered if minimal manifestations are not reached, or the patient has substantial side effects from treatment.”
> “Minimally invasive techniques are preferred with fewer perioperative complications, shorter hospitalization time, and minimal scars.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Intravenous Immunoglobulin and Plasma Exchange

<a id="topic-2.2.2.1.5-1"></a>

###### Short-term and maintenance use: international consensus guidance

> “PLEX and IVIg are appropriately used as short-term treatments in patients with MG with life-threatening signs such as respiratory insufficiency or dysphagia; in preparation for surgery in patients with significant bulbar dysfunction; when a rapid response to treatment is needed; when other treatments are insufficiently effective; and prior to beginning corticosteroids if deemed necessary to prevent or minimize exacerbations.”
> “IVIg and PLEX are probably equally effective in the treatment of severe generalized MG.”
> “The use of IVIg as maintenance therapy can be considered for patients with refractory MG or for those in whom IS agents are relatively contraindicated.”
> “PLEX and IVIg are the mainstay of management in myasthenic crisis.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.5-2"></a>

###### Crisis treatment and maintenance immunoglobulin: Nordic guidance

> “Plasma exchange and intravenous immunoglobulin are the primary treatments recommended for crisis.”
> “Immunoglobulins, given intravenously or subcutaneously, are rarely used as maintenance therapy. A recent study found no steroid‐sparing effect of intravenous immunoglobulin”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.5-3"></a>

###### Systematic review of immunoglobulin in generalized myasthenia gravis

> “We included 12 RCTs (11 with usable data; 515 participants) conducted between 1997 and 2025 in Europe, North America, and Asia. All studies assessed IVIg; none assessed SCIg. Comparators included PLEX (six trials), placebo (five trials), and corticosteroids (one trial).”
> “We found low‐certainty evidence that IVIg may improve symptoms and functional capacity in the medium term in people with MG, compared to placebo, though the effects did not reach commonly used thresholds for clinical significance and were based on sensitivity analyses. Based on moderate‐certainty evidence, IVIg probably also increases the incidence of headache. Based on very low to low‐certainty evidence, IVIg may be less beneficial than PLEX for short‐term improvement in symptoms and may prolong hospital stay, though we found no differences in adverse events.”

Source: [Manolopoulos et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522184/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Complement C5 Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

###### Eculizumab in refractory AChR antibody-positive disease: 2020 consensus update

> “In a phase III international multicenter RCT of 125 patients with refractory generalized nonthymomatous AChR-Ab+ MG (REGAIN), the primary outcome measure of change in the MG-ADL score from baseline to week 26, measured by worst-rank analysis of covariance, was not significantly different ( p = 0.0698) between eculizumab and placebo arms.”
> “Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG (median 9, range 2–9). The role of eculizumab in the treatment of MG is likely to evolve over time. Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals (median 9, range 5–9).”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.6-2"></a>

###### Complement inhibitors and FcRn blockers as second-line treatments: Nordic guidance

> “Several inhibitors of complement proteins have appeared within the last 5 years as a new treatment modality for refractory or difficult‐to‐treat MG patients”
> “The treatment effect is seen within the first 2 weeks and maximal effect appears within the first 2 months.”
> “Due to high drug costs, complement and FcRn inhibitors are recommended only for difficult‐to‐treat patients with severe MG not responding to standard immunosuppressive treatment. Complement and FcRn inhibitors act fast, have a proven effect with an acceptable safety profile, with a selective impact on the immune system. If costs permit and are acceptable, they should be recommended as alternative second‐line treatments.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.6-3"></a>

###### Eculizumab: FDA-labeled indication, dosing, and pivotal trial

> “the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.”
> “900 mg weekly for the first 4 weeks, followed by • 1,200 mg for the fifth dose 1 week later, then • 1,200 mg every 2 weeks thereafter.”
> “A statistically significant difference favoring SOLIRIS was observed in the mean change from baseline to Week 26 in MG-ADL total scores [-4.2 points in the SOLIRIS-treated group compared with -2.3 points in the placebo-treated group (p=0.006)].”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

<a id="topic-2.2.2.1.6-4"></a>

###### Eculizumab biosimilars: FDA-labeled indication

> “The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”

Source: [Bkemv prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761333s008lbl.pdf)

> “the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”

Source: [Epysqli prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761340s024lbl.pdf)

<a id="topic-2.2.2.1.6-5"></a>

###### Ravulizumab: FDA-labeled indication, dosing, and pivotal trial

> “the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.”
> “with maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.”
> “Patients were randomized 1:1 to either receive ULTOMIRIS (n=86) or placebo (n=89) for 26 weeks.”
> “Treatment with ULTOMIRIS demonstrated a statistically significant change in the MG-ADL and QMG total scores from baseline at Week 26 as compared to placebo”
> “Primary Endpoint MG-ADL -1.4 -3.1 -1.6 (-2.6, -0.7) < 0.001”

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

###### Zilucoplan: FDA-labeled indication, dosing, and pivotal trial

> “ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”
> “The recommended dosage of ZILBRYSQ is given once daily as a subcutaneous injection and is dependent on actual body weight”
> “A total of 174 patients were enrolled in Study 1 and were randomized 1:1 to receive either ZILBRYSQ 0.3 mg/kg (n=86) or placebo (n=88) once daily by subcutaneous injection.”
> “At week 12, treatment with ZILBRYSQ demonstrated a statistically significant improvement from baseline compared to placebo for MG-ADL total score and QMG total score”
> “MG-ADL Total Score -4.39 (-5.28, -3.50) -2.30 (-3.17, -1.43) -2.09 (-3.24, -0.95) < 0.001”

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

###### Target of approved complement inhibitors

> “To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.”
> “Zilucoplan is a small macrocyclic peptide that not only binds to C5 to inhibit its cleavage, but also interferes with C5b binding to C6.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Neonatal Fc Receptor Blockers

<a id="topic-2.2.2.1.7-1"></a>

###### Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance

> “Monoclonal antibodies directed at the FcRn receptor's binding site for IgG block recycling and lead to a 60%–70% reduction in circulating IgG.”
> “The treatment can be tailored according to the disease state; new treatment cycles can be administered with signs of symptom worsening or according to a fixed schedule.”
> “The number of treatment responders and the magnitude of the treatment response for FcRn blockers and complement inhibitors seem to be similar. No prospective and controlled head‐to‐head studies have been undertaken.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.7-2"></a>

###### Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials

> “VYVGART is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).”
> “The recommended dosage of VYVGART is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.”
> “Administer subsequent treatment cycles based on clinical evaluation.”
> “A statistically significant difference favoring VYVGART was observed in the MG-ADL responder rate during the first treatment cycle (67.7% in the VYVGART-treated group vs 29.7% in the placebo- treated group [p <0.0001]).”
> “A statistically significant difference favoring VYVGART was observed (LS mean difference [95% CI] = - 1.46 [-2.50 to -0.41]; p-value = 0.0068).”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.1.7-3"></a>

###### Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing

> “VYVGART HYTRULO is indicated for the treatment of adult patients with: • generalized myasthenia gravis (gMG)”
> “The recommended dosage of VYVGART HYTRULO prefilled syringe is 1,000 mg / 10,000 units (1,000 mg efgartigimod alfa and 10,000 units hyaluronidase) administered subcutaneously over approximately 20 seconds to 30 seconds in cycles of once weekly injections for 4 weeks.”
> “VYVGART HYTRULO prefilled syringe may be administered by patients and/or caregivers after proper instruction in subcutaneous injection technique”
> “In Study 3, VYVGART HYTRULO demonstrated a comparable pharmacodynamic effect as compared to the efgartigimod alfa-fcab intravenous formulation, which established the efficacy of VYVGART HYTRULO”

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

###### Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial

> “RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.”
> “Administer the recommended dosage as a subcutaneous infusion using an infusion pump at a rate of up to 20 mL/hour once weekly for 6 weeks.”
> “A statistically significant difference favoring RYSTIGGO was observed in the MG-ADL total score change from baseline [-3.4 points in RYSTIGGO-treated group at either dose vs -0.8 points in the placebo-treated group (p<0.001)].”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

###### Nipocalimab: FDA-labeled indication, dosing, and pivotal trial

> “generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.”
> “30 mg/kg administered once via intravenous infusion over at least 30 minutes. Two weeks after the initial dose administer a maintenance dose of 15 mg/kg via intravenous infusion over at least 15 minutes. Continue the maintenance dose every two weeks thereafter.”
> “In gMG Study 1, a total of 196 patients were randomized 1:1 to receive IMAAVY (n=98) or placebo (n=98).”
> “Primary Endpoint MG-ADL Total Score1 -4.7 (0.33) -3.3 (0.34) -1.5 (-2.4, -0.5) 0.002”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.2.2.1.7-6"></a>

###### Incomplete response to FcRn inhibition

> “Trials of efgartigimod and rozanolixizumab in MG reported a subset of patients who responded poorly despite a reduction in circulating antibodies.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 B-cell Depleting Antibodies

<a id="topic-2.2.2.1.8-1"></a>

###### Rituximab in MuSK and refractory AChR antibody-positive disease: 2020 consensus update

> “A phase II RCT of RTX (Beat-MG) enrolled 52 patients with generalized nonthymomatous AChR-Ab+ MG on a stable regimen of prednisone for 4 weeks or prednisone plus another IS agent for 6 months. 27 Two cycles of RTX 6 months apart were compared to placebo with the primary outcome being a steroid-sparing effect (≥75% reduction in mean daily prednisone requirements in the 4 weeks before week 52 compared with the 4-week period before randomization). The study was designed to assess futility (nonsuperiority). Preliminary results reported that the area under the curve for prednisone was not significantly different between RTX and placebo groups, with 60% on RTX and 56% on placebo achieving the primary outcome.”
> “Rituximab should be considered as an early therapeutic option in patients with MuSK-Ab+ MG who have an unsatisfactory response to initial immunotherapy (median 9, range 4–9). The efficacy of RTX in refractory AChR-Ab+ MG is uncertain. It is an option if patients fail or do not tolerate other IS agents (median 8, range 4–9)”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.8-2"></a>

###### Rituximab as a first-line option in new-onset disease: Nordic guidance

> “In RINOMAX, 47 Swedish patients with new‐onset generalized MG (96% AChR‐antibody MG) were randomized to receive 500 mg rituximab or placebo as an add‐on to the standard of care. [ 43 ] Minimal disease manifestations at 16 weeks, defined as a Quantitative Myasthenia Gravis (QMG) score of 4 or less with a prednisolone dose ≤10 mg and no rescue treatment, was the primary endpoint. This was met by 71% in the active arm and 29% in the placebo group ( p = 0.007).”
> “Rituximab should be considered a first‐line immunosuppressive drug in newly onset disease, as an alternative to steroids and azathioprine. Rituximab should be considered for treatment‐refractory symptoms, although evidence for its effectiveness is weaker than in newly onset disease.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.8-3"></a>

###### Early rituximab: British guideline update

> “Randomised controlled trial evidence now supports early use of rituximab (within 1 year of generalised disease onset), although the evidence is less robust, but still likely to be useful, in established treatment-refractory MG.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

<a id="topic-2.2.2.1.8-4"></a>

###### Systematic review of rituximab in myasthenia gravis

> “We included two RCTs with a total of 99 participants.”
> “Rituximab's effects on symptom severity and functional ability in the long‐term are uncertain. The evidence suggests that rituximab results in little to no difference in its steroid‐sparing effect; however, it probably results in a large reduction in relapse requiring rescue therapy over nine months, based on results from two studies.”

Source: [Dodd et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12224225/)

<a id="topic-2.2.2.1.8-5"></a>

###### Inebilizumab: FDA-labeled indication, dosing, and pivotal trial

> “UPLIZNA is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.”
> “Initial dose: 300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion. • Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months.”
> “In Study 3, a total of 238 patients with gMG were randomized in a 1:1 ratio to receive UPLIZNA or placebo.”
> “A statistically significant difference favoring UPLIZNA was observed in the mean change from baseline in MG-ADL total score (−4.2 points in the UPLIZNA-treated group compared to −2.2 points for placebo, difference of −1.9, 95% CI: −2.9, −1.0; p-value < 0.0001).”

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary

10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and Tice et al. (2022) state that about 20,000 patients with generalized myasthenia gravis are estimated to be intolerant or to have an inadequate response to conventional treatment options. Upward of thirty percent of patients do not benefit from complement inhibition. In claims data from 8833 patients with generalized myasthenia gravis, incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use, compared with 52.3% without, and annual all-cause costs were more than twice as high ($76,381 vs $35,309). Soliris increases the risk of serious meningococcal infections, requires meningococcal vaccination at least 2 weeks before the first dose, and, like Zilbrysq, is available only through a REMS program. Vyvgart may increase the risk of infection. Gilhus et al. list the need for meningococcal vaccination before starting treatment, recommended pneumococcal vaccination, and regular intravenous or subcutaneous injections as limitations, and a company presentation states that 40% of patients discontinue Vyvgart within one year. ICER estimated an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG for eculizumab, and high drug costs limit access to complement inhibitors and FcRn blockers in most countries.

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/); [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/); [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/); [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/); [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf); [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf); [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.1.9-2"></a>

###### Refractory disease despite conventional immunosuppression

> “Definition of refractory MG. PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “However, 10%–20% of patients continue to have long‐standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Currently, it is estimated that about 20,000 patients with generalized MG are intolerant or have an inadequate response to conventional treatment options.”

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)

<a id="topic-2.2.2.1.9-3"></a>

###### Incomplete response to targeted biologics

> “There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.”
> “There is a pressing need for such advancements, especially considering the proliferation of multiple costly treatment options with substantial minorities of patients showing a poor response.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.9-4"></a>

###### Glucocorticoid toxicity and associated costs

> “Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%). Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.”
> “GC acute and chronic toxicities and costs tended to increase with increasing GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

> “although prednisone is still the most consistently effective drug for MG, its side effect burden and that of immunosuppressive as well as the poor response in a large minority”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.9-5"></a>

###### Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors

> “SOLIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1)]. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.”
> “Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of SOLIRIS”
> “Because of the risk of serious meningococcal infections, SOLIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

> “ZILBRYSQ is available only through a restricted program called ZILBRYSQ REMS.”

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

> “One case of meningococcal meningitis occurred, despite vaccination in the OLE and the patient was successfully treated.”
> “Vaccination against Neisseria meningitidis (both meningococcal conjugate Men ACWY and serogroup B or MenB) is required at least 2 weeks before starting treatment with eculizumab.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.9-6"></a>

###### Infection risk with FcRn blockade

> “VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of VYVGART-treated patients compared to 5% of placebo-treated patients) and respiratory tract infections (33% of VYVGART-treated patients compared to 29% of placebo-treated patients)”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.1.9-7"></a>

###### Administration burden: infusion schedules and repeated injections

> “Limitations include the need for meningococcal vaccination before starting treatment, pneumococcal vaccination which is recommended, and regular intravenous or subcutaneous injections.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Administer the SOLIRIS admixture by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

> “The safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.2.2.1.9-8"></a>

###### Treatment persistence with FcRn blockade: company-cited claims data

> “40% of patients discontinue Vyvgart within one year, highlighting continued unmet need and the opportunity for differentiated long-term treatment approaches”
> “20% of Vyvgart franchise growth is being driven by uptake of Hytrulo as patients transition from IV to a complex (up to 90 seconds, multi-step injection) S.C. option”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.1.9-9"></a>

###### Cost and cost-effectiveness of targeted biologics

> “For eculizumab, with an estimated annual cost of $653,100, the incremental cost-effectiveness ratio was $5,210,000 per QALY/evLYG (Table 2). For analyses of efgartigimod, we used a placeholder price of $418,400, which is the midpoint of the potential price range cited by the manufacturer.11 At this estimated price, efgartigimod has an the incremental cost per QALY/evLYG of $2,076,000 (Table 2).”
> “The price for eculizumab is extremely high and is distinctive for the amount by which it exceeds the price needed to reach traditional cost-effectiveness thresholds in the United States.”

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)

> “Very high drug costs have limited the accessibility to treatment in most countries.”
> “In common with complement inhibitors, the availability of FcRn blockers is limited by high drug costs.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Annual all-cause costs were >2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309).”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The roles of complement and FcRn inhibitors are being established, especially in patients unresponsive to conventional therapy; Gilhus et al. (2024) recommend them, because of high drug costs, only for difficult-to-treat patients with severe myasthenia gravis not responding to standard immunosuppressive treatment, and as second- or third-line treatment in severe exacerbations and crisis. The company positions claseprubart as a potential first-line biologic intended to displace C5 complement inhibitors and compete with FcRn blockers, and notes that the C5 efficacy data it compares against come from different trials with different designs and populations. Its target profile is a single self-administered 300 mg/2 mL subcutaneous autoinjector dosed every 2 or 4 weeks, without a boxed warning or REMS; the every-4-week arm and a QMG inclusion criterion were added to the phase 3 trial after a post hoc analysis of MaGic. The company proposes that selective inhibition of the classical pathway may lower the risk of infection from encapsulated bacteria by preserving the lectin and alternative pathways.

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/); [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial); [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="topic-2.2.2.2-2"></a>

###### Company positioning against complement C5 inhibitors and FcRn blockers

> “MaGic Ph. 2 results support a profile with the potential to displace C5 complement inhibitors and compete effectively with FcRns as first-line biologic treatment in growing MG market”
> “Potential for improved efficacy vs. C5 inhibitors with claseprubart may be due to upstream inhibition Upstream inhibition prevents the creation of pro-inflammatory C3a and C3b as well as MAC, potentially providing additional efficacy benefits for AChR+ gMG patients”
> “C5 efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.2-3"></a>

###### Company target product profile: no Boxed Warning or REMS and self-administered autoinjector

> “Targeting convenience of a single, self-administered S.C. 300mg/2mL autoinjector dosed every 2 or 4 weeks”
> “NO BOXED WARNING OR REMS RAPID ONSET WITH DURABLE AND CONSISTENT EFFICACY RAPID SELF-ADMINISTERED AUTOINJECTOR CONVENIENCE”
> “Neurologists would start more patients on a complement inhibitor if they do not have a boxed warning or REMS requirement”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.2-4"></a>

###### Every-4-week subcutaneous dosing evaluated in the phase 3 trial

> “Following an initial loading dose, claseprubart 300mg/2mL will be administered every two or four weeks (Q2W or Q4W) via subcutaneous (S.C.) injection.”
> “Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection.”
> “Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways.”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

> “This post hoc analysis is driving our decision to add a QMG inclusion criteria and a 300mg/2mL S.C. Q4W arm, in addition to a Q2W arm, in our Phase 3 MG study,”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="topic-2.2.2.2-5"></a>

###### Biologic market growth anticipated by the company

> “gMG biologic market growth driven by the introduction of new treatment options, despite limitations”
> “50% of the gMG market is anticipated to consist of branded biologics, driven by differentiated efficacy, safety and more convenient options”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.2-6"></a>

###### Guideline positioning of complement and FcRn therapies

> “several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

> “Complement and FcRn inhibitors are recommended as second‐ or third‐line treatment in severe MG exacerbations and crisis.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### MuSK antibody-positive disease: response to conventional therapies

> “Many patients with MuSK-MG respond poorly to ChEIs, and conventional pyridostigmine doses frequently induce side effects.”
> “Patients with MuSK-MG appear to respond well to corticosteroids and to many steroid-sparing IS agents. They tend to remain dependent on prednisone despite concomitant treatment with steroid-sparing agents.”
> “MuSK-MG responds well to PLEX, while IVIg seems to be less effective.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.3-2"></a>

###### MuSK antibody-positive disease: complement independence and thymectomy

> “The observation of predominant IgG4 antibodies in patients with MuSK MG is indicative of immune response that corresponds with the IgG4 autoimmune diseases ( 9 ) and the antiinflammatory properties of the IgG4 that include the inability to activate complement.”
> “The thymus is normal ( 116 ), and thymectomy does not benefit patients with MuSK with MG”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.3-3"></a>

###### Rituximab response by antibody status

> “A retrospective combined analysis of previously published case reports of 169 patients between January 2000 and August 2015 reported that 72% of MuSK-Ab + MG and 30% of AChR-Ab+ MG patients treated with RTX achieved MM status or better.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-4"></a>

###### Inebilizumab effect by antibody status

| Week 26 outcome | Overall population | Anti-AChR antibody positive | Anti-MuSK antibody positive |
| --- | --- | --- | --- |
| MG-ADL difference from placebo | “-1.9” | “-1.8” | “-2.2” |
| MG-ADL p-value | “<0.0001” | “0.0015” | “0.0297” |
| QMG difference from placebo | “-2.5” | “-2.5” | “-2.3” |
| QMG p-value | “0.0002” | “0.0011” | “NS” |

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="topic-2.2.2.3-5"></a>

###### Seronegative disease: efgartigimod in anti-AChR antibody-negative adults

> “The efficacy of VYVGART for the treatment of adult patients with gMG who are anti-AChR antibody negative was established in an 8-week, randomized double-blind, placebo-controlled study (Study 2 Part A; NCT06298552).”
> “In Study 2 Part A, a total of 119 patients were randomized 1:1 to receive once-weekly infusions for 4 weeks of either VYVGART 10 mg/kg (1,200 mg for those weighing 120 kg or more) (n=58) or placebo (n=61).”
> “Sixty-one percent of patients were triple seronegative (i.e., anti-AChR, anti-MuSK, and anti-low- density lipoprotein receptor-related protein 4 [LRP4] antibodies negative). Thirty-four percent of patients were positive for anti-MuSK antibodies, and 5% of patients were positive for anti-LRP4 antibodies.”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.3-6"></a>

###### Antibody subgroups enrolled in FcRn blocker trials

> “The majority of patients, 89.5% (n=179) were positive for AChR antibodies and 10.5% (n=21) were positive for MuSK antibodies.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

> “Eighty-eight percent (n=134) of patients were positive for AChR antibodies and 10% (n=16) were positive for MuSK antibodies.”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.2.2.3-7"></a>

###### Ocular versus generalized disease

> “In 20% of MG patients, the muscle weakness remains confined to the extraocular muscles”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “The efficacy of IVIg is less certain in milder MG or in ocular MG.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Corticosteroids should be used as the initial IS agent in ocular MG. Steroid-sparing IS agents may be needed when corticosteroids alone are ineffective, contraindicated, or not tolerated”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-8"></a>

###### Age and thymectomy benefit

> “In a post hoc analysis, neither the prednisone dose nor QMG scores were significantly different between the 2 treatment groups in patients 50 years or older.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-9"></a>

###### Claseprubart: baseline QMG subgroup in the phase 2 trial

> “A subgroup analysis of patients enrolled in the MaGic trial with a QMG score ≥10 at baseline which demonstrated an increase in MG-ADL treatment effect for 300mg/2mL Q2W to a 3-point difference from placebo”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Treatment goal of minimal manifestation status: international consensus guidance

> “Goals for the treatment of MG. MGFA Task Force Post-Intervention Status (PIS) classification Minimal Manifestation Status (MMS) or better,3 with no more than grade 1 Common Terminology Criteria for Adverse Events (CTCAE) medication side effects.”
> “MMS: The patient has no symptoms or functional limitations from MG but has some weakness on examination of some muscles.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.4-2"></a>

###### Minimal symptom expression as a patient-reported treatment goal

> “‘Minimal symptom expression’ was defined as MG-ADL total score of 0–1 or MG-QOL15 total score of 0–3.”

Source: [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/)

> “MSE using the MG‐ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

> “MSE, as a patient‐centric endpoint, can be used alongside clinician‐assessed measures and safety measures to support an integrated treatment goal that encompasses both efficacy and tolerability for the treatment of gMG.”

Source: [Meisel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13093530/)

<a id="topic-2.2.2.4-3"></a>

###### Steroid-sparing strategy and tapering

> “A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities.”
> “Tapering of IS drugs is associated with risk of relapse, which may necessitate upward adjustments in dose. The risk of relapse is higher in patients who are symptomatic, or after rapid taper. d. It is usually necessary to maintain some immunosuppression for many years, sometimes for life.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Patients with generalized MG should be given a non‐steroid immunosuppressant to achieve a better clinical response and enable steroid dose reduction.”
> “Tapering of corticosteroids, and non‐steroidal immunosuppressants, should be considered after 1–2 years in patients in stable remission or with minimal symptoms.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.4-4"></a>

###### Monitoring for adverse effects of immunosuppression

> “Patients must be monitored for potential adverse effects and complications from IS drugs. Changing to an alternative IS agent should be considered if adverse effects and complications are medically significant or create undue hardship for the patient.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “All patients on steroids should be monitored for blood pressure, body weight, bone mineral density, blood glucose levels, sleep, and mood problems.”
> “Due to spontaneous disease fluctuations, comorbidities, and changes in life conditions, regular long‐term specialized follow‐up is needed.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.4-5"></a>

###### Monitoring disease activity with MG-ADL and QMG

> “The QMG takes up to 25 min to complete and requires technician training, a hand‐held dynamometer, a spirometer, and a stopwatch.”
> “The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical practice or in clinical trials.”
> “A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-2.2.2.4-6"></a>

###### Physical training and shared goal setting: Nordic guidance

> “Adapted physical training is recommended.”
> “Patients and doctors should together define ambitious treatment goals”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Company target product profile in gMG

> “Achieving this TPP could position claseprubart as a potential best-in-disease biologic and grow the gMG market”
> “Rapid onset with similar or superior MG-ADL to FDA-approved C5 inhibitors with continuous, effective symptom control”
> “Comparable safety to FDA-approved C1s & Classical Pathway inhibitor, leaving the lectin and alternative pathways intact”
> “Comparable convenience to Dupixent with rapid, one-click, self- administered SHL-Molly autoinjector”
> “Targeting >2-point MG-ADL improvement vs. placebo”
> “Targeting no Boxed Warning & REMS”
> “Targeting single 300mg/2mL self-administered S.C. Q2W or Q4W”
> “Safety and efficacy for claseprubart has not been evaluated in head-to-head comparative clinical studies.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.7-2"></a>

###### Company statement of expected benefit and place in gMG treatment

> “As such, we believe claseprubart has the potential to meaningfully transform the standard of care in gMG as a potent, lower dose, lower frequency, self-administered S.C. injection with no FDA Boxed Warning, REMS, or requirement for cycling of treatment such as with FcRn inhibitors.”
> “As it is designed to be a more patient-friendly, predictable, convenient and a less burdensome biologic, claseprubart has the potential to become a first-line biologic treatment option.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
